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CHAPTER 1: INTRODUCTION 
1.1 Spinocerebellar ataxia type 3
The polyglutamine (polyQ) disorders are a group of nine genetically inherited diseases 
caused by CAG triplet repeat expansions in nine distinct genes (Matos et al., 2011). Each disease 
gene translates into a protein with an abnormally expanded polyQ tract. These mutated proteins 
have  increased  propensities  for  misfolding  and  aggregation,  leading  to  neurotoxicity  and 
neurodegeneration (Matos et al., 2011). For all polyQ disorders, the length of the polyQ tract is 
inversely correlated with the age of onset and directly correlated with disease severity (Costa 
Mdo and Paulson, 2012). Huntington’s disease (HD), Spinal-bulbar muscular atrophy (SBMA), 
Dentatorubral-pallidoluysian atrophy (DRPLA), and six spinocerebellar ataxias (SCA 1, 2, 3, 6, 
7, 17) belong to this class (Table 1.1). All polyQ disorders are dominantly inherited, except for 
the X-linked SBMA (Costa Mdo and Paulson, 2012).  
SCA3, or  Machado-Joseph disease (MJD),  is  the most  common dominantly inherited 
ataxia (Costa Mdo and Paulson, 2012). The disease is caused by CAG repeat expansion in the 
ATXN3 gene, located on chromosome 14 (Takiyama et al., 1993). As a result, the polyQ tract of 
the  ataxin-3  protein  increases  from a  normal  range of  ~10-40 repeats  to  a  disease  range of 
~60-80 repeats (Costa Mdo and Paulson, 2012; Matos et al., 2011). The primarily degenerated 
regions are the cerebellar pathways and nuclei, basal ganglia, midbrain, brainstem, and spinal 
cord (Costa Mdo and Paulson, 2012; Matos et al., 2011). Onset of SCA3 occurs in middle to late 
life, with symptoms including progressive ataxia accompanied by complications with speech, 
swallowing,  vision,  muscle  tone,  neuropathy  and more  (Matos  et  al.,  2011).  Over  time,  the 
patients  will  unfortunately  succumb  to  the  disease,  since  there  is  currently  no  cure.  This 
introduction will review the normal functions of ataxin-3 and the role of protein context in polyQ 
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disorders.  Both  topics  can  provide  insight  into  aberrant  mechanisms  in  SCA3 to  target  for 
therapeutics.  
1.2 Physiological functions of ataxin-3
Ataxin-3  is  a  deubiquitinating  enzyme  of  the  MJD  subfamily  (Burnett  et  al.,  2003; 
Winborn  et  al.,  2008).  It  is  found in  both  the  nucleus  and the  cytoplasm,  and is  expressed 
ubiquitously throughout the tissues (Costa et al.,  2004; Paulson et al.,  1997a; Schmidt et al., 
1998; Trottier et al., 1998). As such, ataxin-3 is involved in numerous functions in the cell (Costa 
Mdo and Paulson, 2012). It has several distinct domains that mediate its interactions with other 
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proteins (Figure 1.1). The cysteine protease domain, called the Josephin domain, is located at the 
structured N-terminus (Masino et al., 2003; Masino et al., 2004). Two ubiquitin binding sites 
(UbS1/2) are also located in this region to facilitate the recognition and positioning of ubiquitin 
(Ub) chains for cleavage (Nicastro et al., 2009; Nicastro et al., 2010). In addition to binding Ub, 
UbS2 also binds to the proteasomal shuttle protein, Rad23 (Doss-Pepe et al., 2003; Nicastro et 
al., 2005; Wang et al., 2000). Depending on the isoform, two or three ubiquitin-interacting motifs 
(UIMs) are located at the flexible C-terminus (Goto et al., 1997; Harris et al., 2010; Schmidt et 
al.,  1998).  These  motifs  are  crucial  for  ataxin-3’s  binding  to  polyUb chains,  as  well  as  its 
cleavage specificity (Burnett et al., 2003; Doss-Pepe et al., 2003; Todi et al., 2010). An arginine-
lysine rich motif that is essential for binding to the AAA ATPase, VCP, is located between the 
second UIM and the polyQ tract (Boeddrich et al., 2006; Doss-Pepe et al., 2003). This section 
will  review how ataxin-3’s  protein-binding domains facilitate  its  functions in protein quality 
control, transcriptional regulation, and DNA repair. Potential loss- or gain-of-functions that could 
contribute to SCA3 will be discussed throughout. 
1.2.1 Protein quality control
Ataxin-3  has  been  implicated  in  several  protein  quality  control  pathways.  The  most 
obvious among them is the ubiquitin proteasome system (UPS), due to ataxin-3’s DUB activity 
(Burnett et al., 2003). Ataxin-3 demonstrates cleavage selectivity for chains of 5 or more (Ub) 
moieties  (Winborn et  al.,  2008).  While  this  DUB can cleave both K48- and K63-linked Ub 
chains in vitro,  it  shows the greatest catalytic activity towards K63-linkages, especially those 
within mixed K48-K63 chains (Winborn et al., 2008). Monoubiquitination of ataxin-3, primarily 
at lysine 117, and sumoylation of ataxin-3 at its N-terminus enhance its DUB activity (Pfeiffer et 
al.,  2017;  Todi  et  al.,  2010;  Todi  et  al.,  2009).  In  vivo,  ataxin-3  likely  modulates  the 
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ubiquitination status of many proteins, since total levels of ubiquitination are increased in atxn3 
knockout mouse brains and ataxin-3-depleted human cell lines, while total ubiquitination levels 
are  decreased  when  ataxin-3  is  overexpressed  in  HEK293  cells  (Rodrigues  et  al.,  2010; 
Scaglione et al., 2011; Schmitt et al., 2007; Winborn et al., 2008). 
Ataxin-3 is known to regulate the E3 ligases, C-terminus of Hsc70-interacting protein 
(CHIP) and parkin (Durcan et al., 2011; Scaglione et al., 2011; Winborn et al., 2008). Through 
Ube2w-mediated monoubiquitination of CHIP, ataxin-3 is recruited to edit the length of polyUb 
chains  on  CHIP  substrates  (Scaglione  et  al.,  2011).  Once  polyubiquitinated  substrates 
accumulate, ataxin-3 deubiquitinates CHIP to end the reaction (Scaglione et al., 2011). Initially, 
ataxin-3 was believed to reduce levels of ubiquitinated parkin via the typical deubiquitination 
model (Durcan et al., 2011), but further examination suggests that this regulatory mechanism is 
more complex. Ataxin-3 appears to bind both parkin and the cooperating E2 enzyme (Ubc7), 
stabilize  their  interaction,  and  then  “re-route”  parkin’s  self-monoubiquitination  reaction  onto 
ataxin-3 itself (Durcan et al., 2012). This process is still dependent on ataxin-3’s catalytic activity 
(Durcan et al., 2012). This proposed mechanism is very interesting, since it suggests ataxin-3 is 
capable of 1) an atypical mechanism of deubiquitination and 2) regulating E2 enzymes, not just 
E3s. In the cases of both parkin and CHIP, deubiquitination is partially mediated by ataxin-3’s 
UIMs (Bai et al., 2013; Scaglione et al., 2011). PolyQ-expansion of ataxin-3 seems to heighten 
both interactions, which correlates with decreased levels of these E3s in an SCA3 mouse model 
(Durcan  et  al.,  2011;  Scaglione  et  al.,  2011).  Pathogenic  ataxin-3  also  enhances  parkin’s 
autophagic degradation in cells, which could explain the decreased levels in the mouse model 
(Durcan et al., 2011). Ataxin-3’s normal role in autophagy will be discussed later in this section.
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Recently, p53 was discovered to be another substrate of ataxin-3 (Liu et al., 2016). The 
authors reported that the N-terminus of ataxin-3 is essential for direct binding to p53, and the 
UIMs assist with binding to the ubiquitinated form. Ataxin-3 deubiquitinates p53, stabilizes the 
protein  by  preventing  its  proteasomal  degradation,  and  promotes  transcription  of  p53-target 
genes. Interestingly, pathogenic ataxin-3 has increased binding and DUB activity towards p53. 
This  enhances  p53 stability,  transcriptional  activity,  and  neuronal  loss  in  both  zebrafish and 
mouse brains  (Liu et  al.,  2016).  It  is  worth noting that  another  lab previously reported that 
pathogenic ataxin-3 increased p53 transcriptional activation and subsequent cell death, but this 
was not attributed to an increase in p53 protein levels (Chou et al., 2011b). Nevertheless, the 
work by Liu et al. is exciting because it demonstrates that ataxin-3 can deubiquitinate proteins 
other than ligases (Table 1.2), and these interactions may contribute to SCA3 progression when 
the polyQ tract is expanded.
Ataxin-3 physically interacts with polyubiquitinated proteins, the proteasome, and several 
shuttle proteins, including Rad23, VCP, and ubiquilin-1 (Boeddrich et al., 2006; Doss-Pepe et al., 
Table 1.2: Substrates of Ataxin-3
Substrate Pathway Regulation by Ataxin-3 Reference
E3 ligases
CHIP Ubiquitination Ligase activity Scaglione et al., 2011 Winborn et al., 2008
Parkin Ubiquitination Protein stability Durcan et al., 2011 Durcan et al., 2012
Cell cycle checkpoint mediators
Chk1 DNA repair Protein stability Tu et al., 2017
MDC1* DNA repair Interaction with DNA Pfeiffer et al., 2017
p53 Apoptosis Protein stability Liu et al., 2016
Autophagy regulators
Beclin-1 Autophagy Protein stability Ashkenazi et al., 2017
*It has not yet been confirmed that ataxin-3 directly deubiquitinates MDC1.
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2003; Heir et al., 2006; Nicastro et al., 2005; Wang et al., 2000). This prompted scientists to 
hypothesize that in addition to deubiquitinating substrates, ataxin-3 may facilitate their transfer 
to  the  proteasome degradation  machinery  (Doss-Pepe  et  al.,  2003).  Corroborating  this  idea, 
multiple labs reported that ataxin-3 cooperates with VCP to regulate the degradation of aberrant 
proteins through the endoplasmic reticulum-associated degradation pathway (ERAD)(Arrojo et 
al., 2013; Wang et al., 2006, 2008; Zhong and Pittman, 2006). However, these studies arrived at 
slightly  different  conclusions  as  to  how this  function  is  carried  out.  It  remains  uncertain  if 
ataxin-3  is  mediating  substrate  translocation  across  the  ER membrane  by  VCP (Zhong  and 
Pittman, 2006), or if  it  is modulating the transfer of substrates from VCP to the proteasome 
(Wang et  al.,  2006,  2008).  Also unclear  is  if  ataxin-3’s  catalytic  activity  is  involved in  this 
process.  In terms of polyQ expansion,  one study found that  polyQ-expanded ataxin-3 was a 
greater negative regulator of ERAD substrate degradation than its non-expanded form (Zhong 
and Pittman, 2006).
In addition to the UPS, ataxin-3 may also monitor substrate degradation by autophagy. 
Recently, a study reported that ataxin-3 promotes starvation-induced autophagy through polyQ-
mediated binding to beclin-1 and subsequent stabilization via deubiquitination (Ashkenazi et al., 
2017). The authors also reported that pathogenic ataxin-3 exhibits a dominant-negative effect, 
whereby it out-competes wild type ataxin-3 for binding to beclin-1, but has reduced catalytic 
activity  towards  the  protein.  The  result  is  reduced  levels  of  beclin-1,  presumably  through 
increased  proteasomal  degradation,  and  impaired  starvation-induced  autophagy  in  cells 
(Ashkenazi et al., 2017). This seems to contradict Durcan’s previous observation that pathogenic 
ataxin-3 increased degradation of parkin by autophagy (Durcan et al.,  2011). It  is likely that 
individual  autophagy substrates  are  affected  differently  by the  polyQ expansion of  ataxin-3. 
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Nevertheless, autophagy impairment and reduced beclin-1 levels have also been reported in other 
SCA3  models  (Chang  et  al.,  2016;  Nascimento-Ferreira  et  al.,  2011;  Onofre  et  al.,  2016). 
Furthermore,  multiple  studies  have  reported  improved  phenotypes  with  autophagy-inducing 
compounds and restoration of beclin-1 expression (Chang et al., 2016; Jia et al., 2013; Menzies 
et al., 2010; Nascimento-Ferreira et al., 2013; Nascimento-Ferreira et al., 2011; Onofre et al., 
2016; Silva-Fernandes et al., 2014; Wu et al., 2017). However, this could be due to increased 
clearance  of  aggregated  ataxin-3,  rather  than  a  restoration  of  ataxin-3’s  potential  role  in 
autophagy.
Several lines of evidence suggest a protective role for ataxin-3 against cell stressors.
Ataxin-3 is involved in aggresome formation as a means to sequester misfolded proteins (Burnett 
and Pittman,  2005;  Wang et  al.,  2012).  To accomplish this,  ataxin-3 may edit  the chains  of 
ubiquitinated substrates to signal their transport to the microtubule organizing center.  This is 
supported by ataxin-3’s interactions with HDAC6, dynein, and tubulin (Bonanomi et al., 2014; 
Burnett and Pittman, 2005; Mazzucchelli et al., 2009; Wang et al., 2012). In response to heat 
shock,  ataxin-3 localizes to the nucleus (Reina et  al.,  2010) and upregulates transcription of 
Hsp70 (Reina et al., 2012). Notably, ataxin-3 also protects against heat stress in yeast (Bonanomi 
et  al.,  2017).  When  compared  to  their  wild  type  counterparts,  ataxin-3-knockout  mouse 
fibroblasts exhibit increased cell death and decreased hsp70 activation in response to heat shock 
(Reina et al., 2012; Reina et al., 2010). Interestingly, pathogenic ataxin-3 still accumulates in the 
nucleus and activates the hsp70 promoter upon cell stress, suggesting that it may retain some of 
its protective role (Reina et al., 2012; Reina et al., 2010). However, these effects could just be a 
by-product of expressing a pathogenic protein that has a propensity to misfold and aggregate in 
the nucleus.  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Upon oxidative stress, ataxin-3 translocates to the nucleus and promotes transcription of 
the antioxidant enzyme, SOD2 (Araujo et  al.,  2011; Reina et  al.,  2010).  To accomplish this, 
ataxin-3 binds the transcription factor, FOXO4, and then they jointly bind to the SOD2 promoter. 
Pathogenic ataxin-3 can bind to FOXO4 at a comparable degree to wild type ataxin-3, but it 
exhibits  increased binding to the SOD2 promoter  (Araujo et  al.,  2011).  Ataxin-3’s  increased 
binding impairs activation of SOD2 transcription, likely due to blocking FOXO4 binding to the 
promoter (Araujo et al., 2011). Another study reported that ataxin-3 protects against oxidative 
stress by regulating the interaction between Bcl-X(L) and Bax (Zhou et al., 2013a). Furthermore, 
ataxin-3 protected against oxidative stress in a cellular model of Parkinson’s disease (Noronha et 
al., 2017).
Ataxin-3  is  also  protective  in  Drosophila  models  of  polyQ  diseases,  which  further 
supports the conclusions drawn from the cell-based experiments. Ataxin-3 reduces toxicity in fly 
models of SCA1, SCA3, and HD, likely by preventing aggregation of the disease proteins (Tsou 
et al., 2013; Tsou et al., 2015b; Warrick et al., 2005). However, it is unclear whether proteasome 
activity is required for this process, since two independent studies arrived at opposite conclusions 
(Tsou et al., 2015b; Warrick et al., 2005). Both research groups observed that ataxin-3’s DUB 
activity is required for its protective function (Tsou et al., 2013; Tsou et al., 2015b; Warrick et al., 
2005). Recently, our lab reported that ataxin-3 reduces toxicity by interacting with Rad23 to 
upregulate  expression  of  the  chaperone  protein,  DnaJ-1  (Tsou  et  al.,  2015b).  Presumably, 
DnaJ-1’s refolding of misfolded polyQ proteins is responsible for their improved solubility in 
these Drosophila disease models.  
From  the  studies  outlined  above,  ataxin-3  clearly  reduces  toxicity  caused  by 
environmental stressors in cells and expanded polyQ in Drosophila. However, the significance of 
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these findings has been questioned, due to contradictory results obtained from mouse models of 
polyQ diseases. One study coincided with the results from cells and flies: YAC transgenic mice 
with both an expanded and non-expanded allele for ataxin-3 fared better than mice with only the 
expanded allele (Cemal et al., 2002). A separate research group also tested the benefit of over 
expression of non-expanded ataxin-3 in their transgenic SCA3 model, but they did not observe 
any phenotypic improvement (Hubener and Riess, 2010). Another study observed that knock-out 
of ataxin-3 resulted in a modest increase in the motor deficiency of HD mice, but otherwise the 
phenotype was unaffected (Zeng et al., 2013). Additional studies confirm that ataxin-3 knockout 
mice do not exhibit any obvious adverse effects (Schmitt et al., 2007; Switonski et al., 2011). At 
this  point,  it  is  unclear  if  ataxin-3’s  neuroprotective  function  in  flies  and  cells  translates  to 
mammalian systems.
1.2.2 Transcriptional regulation  
As  mentioned  above,  ataxin-3’s  cytoprotective  mechanisms  include  transcriptional 
activation  of  Hsp70,  SOD2,  and  DnaJ-1.  Alternatively,  ataxin-3  is  known  to  act  as  a 
transcriptional co-repressor under non-stress conditions. This seems to be mediated, at least in 
part, by modulating acetylation pathways. Ataxin-3 interacts with the histone acetyltransferases 
(HATs),  CREB-binding protein (CBP),  p300, and p300/CBP-associated factor to inhibit  their 
downstream transcription (Chai et al., 2001; Li et al., 2002). In accordance with this, ataxin-3 
binds histones H3/H4, and inhibits H4 acetylation by p300 (Li et al., 2002). The N-terminus of 
ataxin-3  appears  to  be  responsible  for  the  histone-binding  function,  while  the  C-terminus 
facilitates interactions with the HATs (Li et al., 2002). Ataxin-3 also recruits histone deacetylase 
3  (HDAC3)  to  reduce  both  histone  acetylation  and  transcription  by  the  matrix 
metalloproteinase-2 promoter (Evert et al., 2006). Pathogenic ataxin-3 is still capable of binding 
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its interacting partners in the transcriptional pathways tested (Chai et al., 2001; Evert et al., 2006; 
Li et al., 2002; Lin et al., 2014). 
Overall, there is a consensus that ataxin-3’s transcriptional regulation is altered when the 
polyQ is expanded, but there is conflicting evidence as to whether the transcriptional activation 
or repression contributes to SCA3. For example, there are instances where pathogenic ataxin-3 
loses its  repressor function,  and gains an activating function (Chai et  al.,  2001; Evert  et  al., 
2006). Conversely, there are studies reporting that pathogenic ataxin-3 represses transcription, 
and alleviating this improves the phenotype in SCA3 mouse models (Chou et al., 2011a; Chou et 
al., 2014). In some cases, pathogenic ataxin-3 increases histone acetylation (Evert et al., 2006), 
but it decreases acetylation in others (Lin et al., 2014). Increasing acetylation levels with HDAC 
inhibitors often improves the phenotype in SCA3 mouse and Drosophila models (Chou et al., 
2011a; Chou et al., 2014; Lin et al., 2014; Wang et al., 2018; Yi et al., 2013), but not always 
(Esteves  et  al.,  2015).  Most  likely,  it  varies  based  on  the  gene  whether  a  loss  or  gain  of 
transcriptional  repression  contributes  to  SCA3 toxicity.  The  different  disease  models  in  use 
could also be contributing to the variability  in  results.  Interestingly,  ataxin-3’s  function as  a 
transcriptional repressor may also be relevant in cancer, since it reportedly inhibits transcription 
of the tumor suppressor, PTEN (Sacco et al., 2014).
1.2.3 DNA repair 
In the past few years, researchers have published exciting findings that identify a novel 
role for ataxin-3 in DNA repair pathways. For example, ataxin-3 interacts with polynucleotide 
kinase 3’-phosphatase (PNKP), a DNA repair enzyme involved in single-strand break repair and 
non-homologous  end joining (Chatterjee  et  al.,  2015;  Gao et  al.,  2015).  Ataxin-3  stimulates 
PNKP’s phosphatase activity so it can signal DNA repair pathways (Chatterjee et al., 2015; Gao 
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et  al.,  2015).  On  the  other  hand,  pathogenic  ataxin-3  inhibits  PNKP’s  phosphatase  activity, 
increases  DNA damage,  activates  the  ATM-mediated damage-response pathway,  and triggers 
p53-dependent apoptosis in cells and SCA3 transgenic mice (Chatterjee et al., 2015; Gao et al., 
2015). These findings are in agreement with a role for ataxin-3 in regulation of p53’s stability 
and subsequent transcription of apoptotic genes (Liu et al., 2016). Furthermore, an increase in 
DNA damage was observed in SCA3 patient brain tissue  (Chatterjee et al., 2015; Gao et al., 
2015). 
Complimentary to these findings, a study using C. elegans reported that ataxin-3 localizes 
to double-stranded break-associated foci, which contain CDC-48(VCP), proteasomes, and the E4 
ligase,  Ufd-2 (Ackermann et  al.,  2016).  These foci  are  associated with  an increase  in  DNA 
Figure  1.1.  The  physiological  functions  of  ataxin-3.  Ataxin-3  has  multiple  protein-
interacting domains that are essential for performing its functions in protein quality control, 
transcription, and DNA repair. There is cross-talk between some of these pathways. 
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damage-dependent apoptosis. However, the presence of ataxin-3 seems to oppose the formation 
of these foci, since ataxin-3 mutants exhibit increased formation of foci and apoptotic signaling 
(Ackermann et al., 2016). These findings raise the possibility that ataxin-3’s function in the UPS 
could also overlap with its regulation of DNA repair pathways.  
Supporting  this  idea,  the  ubiquitination  of  Chk1  and  MDC1,  two  DNA  damage 
checkpoint mediators, were found to be regulated by ataxin-3 (Pfeiffer et al., 2017; Tu et al., 
2017). In response to DNA damage, ataxin-3 deubiquitinates Chk1 to prevent its proteasomal 
degradation (Tu et al., 2017). This allows Chk1 to activate the G2/M DNA damage checkpoint 
and signal for DNA repair mechanisms  (Tu et al., 2017). After prolonged DNA stress, ataxin-3 
dissociates from Chk1 so it can be degraded, thus resuming the cell cycle. The polyQ-expanded 
form of ataxin-3 still interacts with and stabilizes Chk1  (Tu et al., 2017).  Alternatively, ataxin-3 
was also found to localize to sites of DNA damage in a sumoylation-dependent manner (Nishi et 
al.,  2014;  Pfeiffer  et  al.,  2017).  Importantly,  other  labs  have  also  gathered  evidence  for 
sumoylation of ataxin-3 (Almeida et al., 2015; Guzzo and Matunis, 2013; Shen et al., 2005; Zhou 
et al.,  2013b). Once recruited to the DNA, ataxin-3 counteracts the sumo-targeted Ub ligase, 
RNF4, to reduce the ubiquitination of MDC1 (Pfeiffer et al., 2017). This is presumably through 
deubiquitination,  since ataxin-3’s catalytic activity is  required for this  effect.  In this manner, 
ataxin-3 increases MDC1’s interaction with the DNA and the MDC1-mediated recruitment of 
other DNA repair proteins (Pfeiffer et al., 2017).  
Further supporting these collective findings,  loss of  ataxin-3 compromises the Chk1-, 
MDC1-,  and PNKP-mediated DNA damage response pathways and sensitizes cells  to DNA-
damaging agents (Chatterjee et al., 2015; Pfeiffer et al., 2017; Tu et al., 2017). Altogether, these 
studies demonstrate that ataxin-3 is involved in multiple major DNA repair pathways. Future 
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work will enhance our understanding of  this physiological function of ataxin-3 and how it plays 
into SCA3.
1.3 Protein context in polyglutamine disorders
Despite  the  shared mutation in  the  polyQ tract,  each polyQ disorder  presents  with  a 
distinct  set  of  symptoms and  degenerated  brain  regions  (Matos  et  al.,  2011).  This  selective 
degeneration is very intriguing, since most of these disease proteins are widely expressed, and 
many are expressed in the same cell types (Costa Mdo and Paulson, 2012). Furthermore, each 
disorder has its own threshold for when the polyQ expansion of the disease protein switches 
from normal to toxic (La Spada and Taylor, 2003). Humans also possess genes encoding polyQ 
proteins that do not cause disease (Schaefer et al., 2012), leaving scientists to wonder what is so 
significant about the polyQ proteins that cause this class of neurodegenerative diseases. 
For these reasons, the protein context, meaning the normal physiological functions and 
non-polyQ domains of the disease proteins, are thought to play a major role in pathogenesis (La 
Spada and Taylor, 2003; Orr, 2012; Robertson and Bottomley, 2010). For example, non-polyQ 
domains  surrounding  the  polyQ  tract,  including  their  post-translational  modifications,  can 
influence the aggregation and toxicity of the full-length protein (Adegbuyiro et al.,  2017; La 
Spada  and  Taylor,  2003;  Orr,  2012;  Pennuto  et  al.,  2009;  Robertson  and  Bottomley,  2010; 
Saunders  and  Bottomley,  2009).  Protein-interacting  domains  that  are  required  for  a  non-
expanded polyQ protein’s function can provide clues for toxic mechanisms that occur when the 
polyQ tract becomes expanded (La Spada and Taylor, 2003; Orr, 2012; Saudou and Humbert, 
2016). In some cases, the presence or absence of non-polyQ domains in the full-length protein 
can determine whether disease pathogenesis occurs, or not (Klement et al., 1998; Tsuda et al., 
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2005). This section will highlight the most striking evidence for a link between protein context 
and polyQ disease pathogenesis.
1.3.1 Huntington’s disease (HD)
HD is the most common polyQ disorder, so naturally, it is the most studied. There is a 
wealth of information supporting protein context in HD. Many post-translational modifications 
influence huntingtin (htt) toxicity, including phosphorylation (Schilling et al., 2006), acetylation 
(Jeong et al.,  2009), ubiquitination (Jana et al.,  2005), sumoylation (Steffan et al.,  2004) and 
caspase cleavage (Graham et al., 2006). Additionally, several protein-interaction pathways may 
influence HD disease mechanisms (Saudou and Humbert, 2016). Unfortunately, it is unfeasible 
to adequately address all of the studies on HD protein context in this chapter. Instead, this section 
will focus on two domains immediately adjacent to the polyQ tract that influence huntingtin (htt) 
aggregation and toxicity.
Regions  flanking  the  polyQ  domain  of  htt  have  been  found  to  alter  its  aggregation 
propensity. Notably, the first 17 amino acids of htt (N17), located upstream of the polyQ tract, 
promote its aggregation in vitro (Adegbuyiro et  al.,  2017; Hoffner and Djian, 2014).  This is 
believed to occur through stimulation of htt self-association, since N17 can bind to other N17 
domains, as well as the polyQ tract (Hoffner and Djian, 2014; Tam et al., 2009; Thakur et al., 
2009). Blocking N17 can reduce aggregation of pathogenic Htt-exon1, as evidenced by binding 
of the chaperone, TriC, in mammalian cells (Tam et al., 2009). N17 of full-length htt can be post-
translationally  modified  by  phosphorylation  at  serines  13  and  16  (Gu  et  al.,  2009).  The 
significance of this modification has been confirmed in vivo; mutation of these residues to alanine 
prevents motor, behavioral, neurodegenerative, and aggregation phenotypes in BAC transgenic 
mice expressing full-length, mutant htt (Gu et al., 2009).  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Alternatively,  the  polyproline  region  (polyP)  of  htt,  located  at  the  C-terminus  of  the 
polyQ tract, reduces the aggregation propensity of the HD protein. When polyP is added onto the 
C-terminus of a pure polyQ tract, the conformation of the polyQ is altered and its aggregation 
rate is decreased in vitro (Bhattacharyya et al., 2006; Thakur et al., 2009). By preventing the 
polyQ from adopting a β-sheet conformation, polyP protects against htt aggregation (Darnell et 
al.,  2007;  Lakhani  et  al.,  2010).  In  yeast  cells,  deletion of  the  proline-rich  domain leads  to 
increased aggregation and toxicity of polyQ-expanded htt-exon1 (Dehay and Bertolotti, 2006; 
Duennwald et al., 2006). Intriguingly, the effects of the polyP domain are position-specific, since 
addition  of  polyP  to  the  N-terminus  of  the  polyQ  tract  does  not  influence  aggregation 
(Bhattacharyya et al., 2006; Thakur et al., 2009). It is worth noting that the polyP domain is also 
a site of many protein interactions that could potentially influence HD pathogenesis (Khoshnan 
et al., 2004; Passani et al., 2000; Steffan et al., 2000).
One shortfall for many HD studies, including several of the publications mentioned here, 
is that they use a truncated form of the htt protein, containing only exon 1. This is because the htt 
protein is very large (67 exons; ncbi.nlm.nih.gov/gene/3064), and the polyQ domain is located 
within  the  first  exon.  Ideally,  future  work  should  confirm  the  influence  of  htt's  non-polyQ 
domains on htt aggregation with the full-length protein in cell-based and in vivo systems.  
1.3.2 Spinocerebellar ataxia type 1 (SCA1)
Protein context in SCA1 has been firmly established by work conducted in the Zoghbi 
and Orr labs. Nearly 2 decades ago, they discovered that ataxin-1’s nuclear localization signal is 
essential  for  pathogenesis  in  SCA1  mice  (Klement  et  al.,  1998).  Several  years  later,  they 
observed  that  ataxin-1  is  phosphorylated  at  serine  776,  and  mutating  this  serine  to  alanine 
substantially  reduces  toxicity  in  SCA1  transgenic  mice  (Emamian  et  al.,  2003).  This 
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phosphorylated residue was also found to be required for its interaction with the 14-3-3 protein 
(Chen  et  al.,  2003).  The  same  study  reported  that  14-3-3  binding  to  ataxin-1  enhances 
polyglutamine toxicity  in  a  Drosophila  model  of  SCA1,  by slowing degradation of  ataxin-1 
(Chen et al., 2003). Phosphorylation of serine 776 is also critical for ataxin-1’s interaction with 
the splicing factor, RBM17, and this interaction is promoted by increasing polyQ tract length 
(Lim et al.,  2008).  Interestingly, modulating levels of RBM17 influences ataxin-1 toxicity in 
Drosophila;  overexpression  enhances  toxicity,  while  loss  of  one  RBM17  allele  suppresses 
toxicity (Lim et al., 2008).
The AXH domain of ataxin-1 also influences the SCA1 protein’s properties. This domain 
is the binding site for many of ataxin-1’s interactions with other proteins, including its own self-
association,  and  is  at  least  partially  responsible  for  ataxin-1’s  function  as  a  transcriptional 
repressor (Chen et al., 2004; de Chiara et al., 2003; de Chiara et al., 2005). Studies conducted by 
the Orr and Zoghbi labs demonstrated that the AXH domain of ataxin-1 directly binds to the 
Drosophila transcription factor, Senseless, and its mammalian homologue, Gfi-1 (Tsuda et al., 
2005). Ataxin-1 negatively regulates the expression levels of Senseless/Gfi-1, but deletion of the 
AXH domain increases the transcription factor’s stability and reduces overall polyQ toxicity (de 
Chiara  et  al.,  2005;  Tsuda  et  al.,  2005).  Alternatively,  the  AXH domain  is  also  the  site  of 
ataxin-1’s interaction with Capicua, a transcriptional repressor that modulates toxicity in SCA1 
(Fryer et al., 2011; Lam et al., 2006). Ongoing research continues to elucidate the mechanisms 
and outcomes of the Capicua-AXH interaction in this disease (Lu et al., 2017).
1.3.3 Spinal and bulbar muscular atrophy (SBMA)
Protein context also plays a role in SBMA, the only X-linked, recessive polyQ disorder 
(Costa Mdo and Paulson, 2012).  The expanded protein in this case is  the androgen receptor 
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(AR), whose nuclear receptor domains are required for disease progression. For instance, the 
nuclear  localization signal,  as  well  as  the ligand-binding domain that  binds testosterone,  are 
required  for  pathogenesis  in  fly  and  mouse  models  of  SBMA (Montie  and  Merry,  2009; 
Takeyama et al., 2002). Additionally, experiments conducted in Drosophila show that the AR’s 
DNA-binding domain and AF-2 interacting domain are also required for toxicity (Nedelsky et 
al.,  2010).  Furthermore,  altering the  levels  of  testosterone modulates  toxicity  of  AR in  vivo 
(Katsuno et al., 2002; Takeyama et al., 2002).  
Conversely, a leucine-rich region immediately preceding the AR's polyQ tract may work 
to prevent toxicity in SBMA; this leucine-rich domain reduces aggregation of an N-terminal AR 
fragment  in  vitro  by  maintaining  the  alpha-helical  conformation  of  the  polyQ  tract 
(Eftekharzadeh et al., 2016). On the other hand, another sequence in AR’s N-terminus, located 
downstream of the polyQ tract, appears to enhance AR fibrilization (Oppong et al., 2017). The 
significance of these domains has not been tested with a full-length AR protein in an in vivo 
setting, but such studies could provide valuable insight into aggregation mechanisms in SBMA.
1.3.4 Spinocerebellar ataxia type 3 (SCA3)  
The catalytic Josephin domain of ataxin-3 is known to promote aggregation of the SCA3 
protein. Both wild type and mutant ataxin-3 form SDS-soluble aggregates in vitro (Chow et al., 
2004; Ellisdon et al., 2006; Gales et al., 2005; Masino et al., 2004) and are present in nuclear 
inclusions  in  vivo  (Fujigasaki  et  al.,  2000;  Fujigasaki  et  al.,  2001;  Lieberman et  al.,  1999), 
suggesting that this process can occur independently of an expanded polyQ tract. However, only 
ataxin-3  with  expanded  polyQ  can  form  SDS-insoluble  aggregates  (Ellisdon  et  al.,  2006; 
Natalello et al., 2011). Notably, aggregation of isolated Josephin occurs in a manner very similar 
to full-length, non-expanded ataxin-3, where its conformation transitions from an alpha-helix to a 
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beta-sheet (Ellisdon et al., 2006; Masino et al., 2011; Masino et al., 2004; Natalello et al., 2011). 
Together, these findings have led to the hypothesis that ataxin-3 aggregation occurs through a 
two-step mechanism in which aggregation is  first  initiated by the Josephin domain and then 
propagated by the polyQ expansion (Ellisdon et al., 2006; Scarff et al., 2015; Silva et al., 2017).
Post-translational modifications to ataxin-3 also appear to influence its aggregation and 
toxicity.  Sumoylation  at  lysine  356 reduces  ataxin-3  aggregation  in  vitro  and  in  rat  cortical 
neurons  (Almeida  et  al.,  2015).  Intriguingly,  this  modification  also  enhances  ataxin-3’s 
interaction with the AAA ATPase,  VCP/p97 (Almeida et  al.,  2015),  which will  be discussed 
further in Chapter 4. GSK3β phosphorylates ataxin-3 on serine 256, and ataxin-3’s aggregation is 
increased in mammalian cells when this site is mutated to a non-phosphorylatable alanine (Fei et 
al.,  2007).  This  is  an  interesting  finding,  since  the  authors  also  observed  that  GSK3β 
phosphorylates  pathogenic  ataxin-3  less  than  the  non-pathogenic  form  (Fei  et  al.,  2007). 
Additionally, phosphorylation of ataxin-3 at serine 12 by an unidentified kinase was shown to 
reduce ataxin-3 aggregation in cortical neurons and prevent neuronal loss in a lentiviral rat model 
of  SCA3  (Matos  et  al.,  2016).  Moreover,  phosphorylation  at  serine  residues  29  (Josephin 
domain), 340 (UIM3), and 352 (UIM3) increase ataxin-3’s nuclear localization (Mueller et al., 
2009; Pastori et al., 2010), which is a critical determinant of SCA3 pathogenesis (Bichelmeier et 
al.,  2007;  Paulson  et  al.,  1997b).  Altogether,  these  studies  indicate  that  post-translational 
modifications have the potential to accelerate or attenuate SCA3 progression.
1.4 Conclusions  
Although the polyQ disorders have unifying features,  it  is  their  mutated proteins that 
make each disease unique. Each polyQ protein has their own set of physiological functions that 
can  go  awry  to  cause  disease.  Research  into  ataxin-3’s  roles  in  protein  quality  control, 
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transcriptional regulation, and DNA repair elucidates several pathways that are altered in SCA3. 
Interestingly, some of these functions seem to overlap: transcriptional regulation contributes to 
protection against cell stress, DUB activities facilitate DNA repair and transcription, etc (Figure 
1.1). Furthermore, identification of the structural domains that are required for these functions 
opens  the  door  to  the  development  of  targeted  therapeutics.  Future  efforts  to  merge  our 
understanding of sequence domains and post-translational modifications that modulate toxicity 
with the normal physiological functions of ataxin-3 will enhance our understanding of SCA3 and 
how to treat it.  
Alternatively, while protein context makes the diseases unique, it is evident that there are 
some  shared  mechanisms.  Ataxin-3,  ataxin-1,  htt,  AR,  each  exhibit  increased  toxicity  when 
localized to the nucleus. All of the proteins have at least one domain that tends to self-associate 
and  promote  aggregation.  The  ability  of  post-translational  modifications  to  influence  polyQ 
protein aggregation and toxicity is  also a unifying feature.  Therefore,  new discoveries about 
protein context in one polyQ disorder have the potential to enhance our understanding of the 
disease class as a whole. 
For all of these reasons, my thesis explores the interactions between ataxin-3 and two of 
its protein-binding partners: Rad23 and VCP. These studies demonstrate that Rad23 and VCP can 
modulate the toxic properties of ataxin-3 in vivo, thus providing novel information about protein 
context in SCA3.  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CHAPTER 2: Materials and Methods
Adapted from: 
Published: Sutton JR, Blount JR, Libohova K, Tsou W-L, Joshi GS, Paulson HL, Costa MDC, 
Scaglione KM, Todi SV (2017). Interaction of the polyglutamine protein ataxin-3 with Rad23 
regulates toxicity in Drosophila models of Spinocerebellar Ataxia Type 3.  Human Molecular 
Genetics 26, 1419-1431.
Under review: Ristic GR*, Sutton JR*, Libohova K, Todi SV (2018). Toxicity and aggregation 
of  the  polyglutamine  disease  protein,  ataxin-3  is  regulated  by  its  binding  to  VCP/p97  in 
Drosophila melanogaster. Neurobiology of Disease. *- these authors contributed equally to this 
manuscript.
Antibodies:  Anti-Ataxin-3  (mouse  monoclonal  1H9,  1:500-1,000;  Millipore)  (rabbit  poly- 
clonal, 1:15,000; (Paulson et al., 1997a)); anti-VCP (rabbit monoclonal, 1:1,000; Cell Signaling 
Technology); anti-tubulin (mouse monoclonal T5168, 1:10,000; Sigma-Aldrich); anti-HIS (rabbit 
monoclonal 1:1,000; Cell Signaling); anti-HA (rabbit monoclonal, 1:500-1,000; Cell Signaling 
Technology); anti-GAPDH (mouse monoclonal MAB374, 1:500; Millipore); anti-lamin (mouse 
monoclonal  ADL84.12-5,  1:1,000;  Developmental  Studies  Hybridoma  Bank);  peroxidase-
conjugated  secondary  antibodies  (goat  anti-rabbit  and  goat  anti-mouse,  1:5,000;  Jackson 
Immunoresearch).  
Drosophila lines: Husbandry was conducted at 25°C on standard cornmeal food at 40%-60% 
humidity in a regulated diurnal environment. SCA3 flies expressing pathogenic ataxin-3 with 
77-80 polyQ repeats were generated by cloning into the pWalium10-moe vector (Perrimon lab). 
“HNHH”, “UbS2*Mild”, and “UbS2*Severe” mutations were generated on the pathogenic ataxin-3 
backbone using the QuikChange mutagenesis kit (Agilent), then cloned into the pWalium10-moe 
vector.  Rad23-overexpressing  flies  were  generated  by  using  HIS6-tagged  Drosophila  Rad23 
cloned into the pWalium10-moe vector. Injections (Duke University Model Systems) were into y, 
w;  +;  attP2.  The  following  stocks  from purchased  from the  Bloomington  Drosophila  Stock 
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Center: isogenic host strain for GMR-Gal4 (#8121), attP2 (#36303), DnaJ-1 RNAi (#32899), 
VCP RNAi lines (#32869, #35608), UAS-DnaJ-1 (#30553), and UAS-polyQ78 (#8141). Rad23 
RNAi (#30498)  and its  isogenic  line  (#60000)  were  purchased from the  Vienna Drosophila 
RNAi Center. The  following  lines  were  gifts:  sqh-Gal4  driver  (Dr.  Daniel  P.  Kiehart,  Duke 
University),  elav-  Gal4(GS) driver  (Dr.  Robert  Wessells,  Wayne State University),  elav-Gal4 
driver (Dr. Daniel F. Eberl, University of Iowa).  
Longevity assay: Upon eclosion, approximately 25 male and female adults were collected and 
aged in conventional cornmeal fly media or RU-486-containing media (Nicholson et al., 2008; 
Osterwalder et al., 2001; Roman and Davis, 2002; Sujkowski et al., 2015) at 25°C. Flies were 
transferred to vials with fresh food every 2–3 days. Each vial was checked for death daily, until 
all  flies  were  dead.  Longevity  comparisons  were  restricted  to  fly  lines  in  the  same  genetic 
background,  since  flies  from different  backgrounds  can  have  different  lifespans  (Paaby  and 
Schmidt, 2009; Spencer et al., 2003).  
Motility Assay (Negative Geotaxis): Approximately 10 adult flies per vial were forced to the 
bottom by tapping on the bench. The number of flies that reached the top at 5, 15 and 30 seconds 
was recorded. The assay was conducted once a week for 4 weeks. Flies were transferred to new 
vials  1  hour  before  the  assay  was  conducted,  and  every  2–3  days  for  the  duration  of  the 
experiment.  
Ataxin-3 Pulse-Chases  in Drosophila:  Fly crosses  were  set  up in  standard cornmeal  media 
under the conditions described in “Drosophila lines”. After eclosion, adult offspring possessing 
transgenes  for  the  inducible  elav-Gal4(GS)  driver  and UAS-Ataxin-3(SCA3)-Intact  or  UAS-
Ataxin-3(SCA3)-HNHH were transferred to cornmeal media containing RU-486 (Nicholson et 
al., 2008; Osterwalder et al., 2001; Roman and Davis, 2002; Sujkowski et al., 2015). Expression 
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of UAS-Ataxin-3(SCA3)-Intact was induced in the RU-486-containing media for 7 or 14 days; 
expression of UAS-Ataxin-3(SCA3)-HNHH was induced for 10 or 21 days. At the end of the 
induction period, flies were transferred back to the standard cornmeal media for the chase period. 
Flies were collected for western blot analysis at  day 0,  1,7,  14, and 21 of the chase period. 
Motility and western blot analysis were carried out as described above.  
Histology: Wings and proboscises were removed from male, adult flies and bodies were fixed 
overnight in 2% glutaraldehyde/2% paraformaldehyde in Tris-buffered saline with 0.1% Triton 
X-100. Fixed adults were then dehydrated in a series of 30, 50, 75, and 100% ethanol washes for 
1 hour each, then washed in propylene oxide overnight. Dehydrated flies were embedded in Poly/
Bed812 (Polysciences) and sectioned at 5 µm. Sections were stained with toluidine blue.  
Western blotting: Three to 5 whole flies, 10 to 15 dissected fly heads, or 10 larvae per group 
were homogenized in hot lysis buffer (50 mM Tris pH 6.8, 2% SDS, 10% glycerol, 100mM 
dithiothreitol),  sonicated,  boiled  for  10  minutes,  and  centrifuged  at  top  speed  at  room 
temperature  for  10  min.  Samples  were  electrophoresed  on  4-20%  gradient  gels  (BioRad). 
Western blots were developed and quantified using a CCD-equipped VersaDoc 5000MP system 
and  Quantity  One  software  (Bio-Rad).  For  direct  blue  staining,  PVDF  membranes  were 
submerged for 5 minutes in 0.1% Direct Blue 71 (Sigma-Aldrich) stock solution in ultra pure 
water, dissolved in 40% ethanol and 10% acetic acid solvent. Membrane was rinsed briefly in 
solvent, then ultra pure water, air dried, and imaged.  
Differential Centrifugation: Five whole flies per group were lysed in 200 μl of NETN buffer 
(50 mM Tris, pH 7.5, 150 mM NaCl, 0.5% Nonidet P-40), supplemented with protease inhibitor 
cocktail (PI, SigmaFast Protease Inhibitor Cocktail Tablets), sonicated, and centrifuged at 20,000 
x g for 30 minutes at 4  ̊C. The supernatant was transferred to a new tube and quantified by the 
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BCA assay. The pellet was resuspended in 200 μl of PBS + 1% SDS, vortexed, and boiled. Ten 
μg of the supernatant fraction and 7 μl of the pellet fraction were supplemented with 6x SDS, 
boiled, and loaded onto 4-20% gradient gels for western blot analysis.  
Nuclear Cytoplasmic Extraction:  Experiments were conducted using the ReadyPrep Protein 
Extraction Kit ((Cytoplasmic/Nuclear), BioRad) to enrich cytoplasmic and nuclear proteins. Five 
whole  adult  flies  were  lysed  in  cytoplasmic  extraction  buffer  (Bio-  Rad).  Nuclei  were 
resuspended in Protein Solubilization Buffer (BioRad). Samples were analyzed by western blot.  
Quantitative RT-PCR: Total RNA was extracted from larvae or adult flies using TRIzol (Life 
Technologies).  Extracted  RNA  was  treated  with  TURBO  DNAse  (Ambion)  to  eliminate 
contaminating DNA. Reverse transcription was carried out with the high-capacity cDNA reverse 
transcription kit (ABI). Messenger RNA levels were quantified by using the StepOnePlus Real-
Time PCR System with Fast  SYBR Green Master Mix (ABI).  rp49 was used as an internal 
control. Primers: 
SCA3 - F: 5’ GAATGGCAGAAGGAGGAGTTACTA - 3’ 
SCA3 - R: 5’ GACCCGTCAAGAGAGAATTCAAGT - 3’ 
rp49-F: 5’ -AGATCGTGAAGAAGCGCACCAAG- 3’ 
rp49-R: 5’ -CACCAGGAACTTCTTGAATCCGG- 3’  
Cell lines, plasmids, transfection & chemicals: HeLa and HEK293 cells were purchased from 
ATCC and cultured in DMEM supplemented with 10% FBS and 5% Penicillin-Streptomycin 
under conventional conditions. The day before transfection, cells were seeded in 6- or 12-well 
plates.  Cells  were  transfected  using  Lipofectamine  LTX  (Invitrogen)  as  directed  by  the 
manufacturer. Twenty-four hours after transfection, cells in 12-well plates were lysed in boiling 
SDS lysis buffer for western blot analysis. Cells in 6-well plates were harvested in PBS, pelleted 
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by centrifugation at 500 x g for 5 minutes at 4°C, and frozen at -80°C for immunoprecipitation 
experiments. Non-pathogenic ataxin-3 constructs were in pcDNA3.1-HA. Pathogenic ataxin-3 
constructs  were  in  pFLAG-CMV6a.  VCP  construct  was  in  pEGFP.  Cycloheximide  (A.G. 
Scientific) dissolved in ultra-pure water, was used at 50 mg/ml.  
Co-Immunoprecipitation:  For  co-IPs  from  fly  lysates,  30-50  fly  heads  per  group  were 
homogenized  through  mechanical  disruption  in  PBS  +  PI,  briefly  sonicated,  and  then 
supplemented with the equal  volume of  NETN + PI.  Lysates  were vortexed briefly every 5 
minutes for a total of 30 minutes, centrifuged at 5,000 x g for 5 minutes at 4 ̊C, and supernatant 
was transferred to 30 μl slurry of anti-HA bead-bound antibody (Sigma- Aldrich). Beads with 
lysates were tumbled at 4 ̊C for 4 hours. For co-IPs from cell lysates, HEK293 or HeLa cells 
were transfected and harvested as described under “Cell Lines, Plasmids, and Transfections”. 
Cell pellets were lysed in 500 mL of NETN+PI, vortexed briefly every 5 minutes for a total of 30 
minutes, and centrifuged at 12,000 x g for 15 minutes at 4 ̊C. Supernatants were transferred to 30 
μl slurry of anti-FLAG bead-bound antibody (Sigma-Aldrich). Beads with lysates were tumbled 
at 4  ̊C for 4 hours. For in vitro pulldowns, 1.5 mL of bacterial lysate containing GST, GST-
Ataxin-3(SCA3)-Intact, or GST-Ataxin-3(SCA3)-HNHH was tumbled with 20 μl of glutathione 
sepharose slurry for 30 minutes. Both Ataxin-3(SCA3) constructs contained 80 polyQ repeats. 
GST-Atax- in-3(SCA3)-Intact and Ataxin3(SCA3)-HNHH supernatants were replaced with 1.5 
mL of fresh bacterial lysate before tumbling all lysates for an additional 30 minutes. Forty whole 
flies were homogenized in 500 μl of NETN + PI, sonicated, and centrifuged at 15,000 x g for 15 
minutes at 4 ̊C. The bacterial lysate was removed from the beads, beads were rinsed with NETN 
+ PI, the fly lysate was distributed evenly among the 3 experimental groups, and samples were 
tumbled  for  2  hours  at  4  ̊C.  Bead-bound complexes  from all  co-immunoprecipitations  were 
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rinsed thrice with NETN + PI, then eluted with heat and Laemmli buffer.  
Protein Purification:  Glycerol stocks of BL21 cells transformed with pGEX6p1, pGEX6p1-
Ataxin-3(SCA3)-Intact, or pGEX6p1-Ataxin-3(SCA3)-HNHH were used to inoculate 10 mL of 
LB  +  50  ug/mL ampicillin.  Both  Ataxin-3(SCA3)  constructs  contained  80  polyQ  repeats. 
Cultures were grown overnight at 37 ̊C, then used to inoculate 500 mL of LB + ampicillin, which 
was grown for an additional 1.5 hours to OD600=.60. Protein expression was induced with 0.5 
mM of isopropyl-1-β-D-galactopyranoside (A. G. Scientific) for 4h at 30 °C. Bacterial cells were 
pelleted by centrifugation at 4,500 x g for 10 minutes at 4°C. Pellets were lysed in NETN buffer, 
sonicated, centrifuged, aliquoted, and frozen at -80°C.  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CHAPTER 3: Interaction of the polyglutamine protein, ataxin-3, with Rad23 regulates 
toxicity in Drosophila models of Spinocerebellar ataxia type 3
Published: Sutton JR, Blount JR, Libohova K, Tsou W-L, Joshi GS, Paulson HL, Costa MDC, 
Scaglione KM, Todi SV (2017). Interaction of the polyglutamine protein ataxin-3 with Rad23 
regulates toxicity in Drosophila  models of Spinocerebellar ataxia type 3.   Human Molecular 
Genetics 26, 1419-1431. 
3.1 Introduction  
Polyglutamine  (polyQ)-dependent  diseases  comprise  a  class  of  neurodegenerative 
disorders  characterized  by  abnormal  CAG nucleotide  repeat  expansions  in  the  disease  gene 
(Costa Mdo and Paulson, 2012). These repeats translate into an abnormally long polyQ tract, 
resulting  in  subsequent  misfolding  and  aggregation  of  the  disease  protein  in  neurons  and, 
ultimately, neuronal dysfunction and death. Among these disorders, Spinocerebellar Ataxia Type 
3 (SCA3, or Machado-Joseph Disease), is the most common dominantly inherited ataxia in the 
world (Costa Mdo and Paulson, 2012; Matos et al., 2011). Onset occurs in mid to late life, with 
degeneration observed in cerebellar  pathways and nuclei,  dentate  nuclei,  pontine nuclei,  and 
basal ganglia. Symptoms include ataxia, dysarthria, dystonia, ophthalmoplegia, spasticity, and 
neuropathy (Costa Mdo and Paulson, 2012). There is no cure for SCA3. 
SCA3 is caused by expansion of a CAG tract in ATXN3 from 22–42 repeats to a disease 
range of 52–84, leading to the translation of a pathogenic form of the ataxin-3 protein with 
expanded polyQ (Costa Mdo and Paulson, 2012; Matos et al., 2011). Ataxin-3, a deubiquitinating 
enzyme, edits ubiquitin chains on substrates (Scaglione et al., 2011; Winborn et al., 2008); it has 
been reported to function in protein quality control and transcriptional regulation (Costa Mdo 
and Paulson, 2012; Reina et al., 2012; Sacco et al., 2014; Scaglione et al., 2011; Todi et al., 
2010),  and is  neuroprotective  in  Drosophila  melanogaster,  where  it  suppresses  degeneration 
from various polyQ proteins (Burr et al., 2014; Tsou et al., 2013; Tsou et al., 2015b; Warrick et 
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al., 2005). Ataxin-3 also protects against various stressors in mammalian cell culture (Chatterjee 
et al., 2015; Reina et al., 2012; Reina et al., 2010; Zhou et al., 2013a). 
The N-terminal catalytic domain of ataxin-3 contains two ubiquitin-binding sites that can 
bind mono-ubiquitin (Nicastro et al., 2009; Nicastro et al., 2010) Ubiquitin-binding site 2 (UbS2) 
also binds to the proteasomal shuttle  proteins,  Rad23/hHR23A and B (Nicastro et  al.,  2009; 
Nicastro et al., 2005; Nicastro et al., 2010; Wang et al., 2000). According to our earlier published 
work, proteasomal degradation of ataxin-3 is regulated by the direct interaction between UbS2 
and Rad23 (Blount et al.,  2014). When Rad23 is bound to UbS2, ataxin-3 is protected from 
degradation  (Figure  3.1A).  Disrupting  this  interaction  decreases  the  steady  state  levels  of 
ataxin-3 in the cell. While this previous work showcased the importance of the ataxin-3-Rad23 
interaction for the SCA3 protein’s turnover, it did not directly test whether this interaction is 
critical for ataxin-3-dependent toxicity. In other words, does UbS2 of ataxin-3 directly modulate 
SCA3 pathogenicity? More importantly, should UbS2 be targeted to protect against SCA3, since 
it regulates overall cellular levels of ataxin-3? 
Here, we show that disrupting UbS2 of disease-causing ataxin-3 decreases the levels of 
the pathogenic ataxin-3 protein, but greatly enhances its toxicity in vivo. Further investigations 
indicate that this increase in toxicity is due to a reduction in ataxin-3’s neuroprotective function 
against itself, which is mediated by the UbS2-Rad23 interaction and depends on the chaperone 
partner, DnaJ-1. Our data demonstrate a critical role for the interaction of ataxin-3 with Rad23 in 
the regulation of this polyQ protein’s abundance, function, and pathogenicity. 
3.2 Results  
3.2.1 Modulating levels of Rad23 influences ataxin-3’s toxicity in Drosophila  
To examine the function of the interaction between UbS2 of ataxin-3 and Rad23, we used 
 28
a  transgenic  fly  model  of  SCA3  that  we  recently  generated  by  using  the  phiC31-targeted 
integration  system  (Groth  et  al.,  2004).  The  phiC31  system  yields  a  similar  expression  of 
transgenes among different fly lines, due to site-specific integration (Groth et al., 2004), in our 
case into attP2 on the third chromosome of the fly. This method allows for direct comparisons 
among the  different  transgenic  lines  we generated  (Figure 3.1B).  Our  Drosophila  model  of 
SCA3 expresses untagged, full-length, human pathogenic ataxin-3 under the control of the Gal4/
UAS system. We also generated a control line that contains the empty host vector inserted into 
attP2 (Tsou et al., 2015a) and another line that expresses wild-type, human ataxin-3, inserted at a 
different site than attP2 (Tsou et al., 2013).  
When pathogenic ataxin-3 (Ataxin-3(SCA3)) is expressed throughout the fly, it leads to 
some lethality at late pharate adult stages and during eclosion from the pupal case (Figure 3.1C). 
Those flies that mature into adulthood only live up to 30 days, as opposed to the control flies that 
live up to 100 days (Figure 3.1D). 
Previously, we reported that reducing the levels of endogenous Rad23 through RNAi by 
approximately 50%, as determined through qRT-PCR, or by removing one copy of its  gene, 
decreased  ataxin-3  protein  levels  and  noticeably  improved  degeneration  in  Drosophila  eyes 
expressing pathogenic ataxin-3 with an intact UbS2 ((Blount et al., 2014); other supporting data 
not shown). We recapitulated this effect by reducing endogenous Rad23 levels in all the tissues 
of the fly through RNAi. We observed improved adult longevity compared to sibling SCA3 flies 
without Rad23 knockdown (Figure 3.1E). Based on our earlier work with various Gal4 drivers 
and different polyQ and non-polyQ constructs (Blount et al., 2014; Ristic et al., 2016; Tsou et al., 
2013; Tsou et al., 2015a; Tsou et al., 2015b), improved longevity from pathogenic ataxin-3 when 
Rad23 is knocked down through UAS-RNAi is not due to a dilution effect of the Gal4 driver co-
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Figure 3.1.  Rad23 influences Ataxin-3(SCA3)-dependent toxicity. (A)  Model depicting how Rad23 influences ataxin-3’s degradation, 
based  on  studies  from Blount  et  al.,  2014.  The  ubiquitin-interacting  motifs  (UIMs)  of  ataxin-3  bind  ubiquitin  chains  on  proteasome 
substrates, facilitating the interaction of ataxin-3 with this machinery. Once at the proteasome, in the absence of interaction with Rad23, 
ataxin-3 is degraded. If ataxin-3 interacts with Rad23 through UbS2, it is rescued. (B) Summary of transgenic Drosophila lines used. (C) 
Observations with ubiquitous expression of pathogenic ataxin-3 with or without Rad23 overexpression. In this panel and rest of the figures, 
unless otherwise noted, flies were heterozygous for all transgenes. (D) Longevity of flies ubiquitously expressing pathogenic ataxin-3 or the 
empty host  vector  inserted into attP2.  (E)  Longevity of  flies  ubiquitously expressing pathogenic ataxin-3 without  or  with UAS-RNAi 
targeting Rad23. A control line was included that expresses Rad23 RNAi in the absence of ataxin-3. Flies were siblings from the same 
crosses and on a different background (y-w-) than flies in the rest of this figure (w1118). (F) Western blots from independent lysates of whole 
flies  ubiquitously  expressing  the  specified  transgenes.  Means  ±  SD.  Asterisks:  P<  0.05  from  Student’s  t-tests  compared  to  UAS-
Ataxin-3(SCA3) without exogenous Rad23. When quantifying ataxin-3 protein levels for (-)Rad23 flies, lane 4 was set to 100%. Lane 5 was 
not quantified, due to the bubble disrupting the ataxin-3 band. (G) Longevity of flies ubiquitously expressing pathogenic ataxin-3 with or 
without Rad23 overexpression.
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expressing ataxin-3 and the knockdown construct. 
Conversely  to  Rad23  knockdown,  exogenous  Rad23  noticeably  increases 
Ataxin-3(SCA3) protein  levels  (Figure 3.1F).  This  increase  in  protein  levels  coincides  with 
higher lethality (Figure 3.1C). Almost all of the SCA3 flies that co-express Rad23 die as pharate 
adults, before they eclose from the pupal case. Very few adult flies co-expressing Rad23 and 
Ataxin-3(SCA3) eclose successfully (Figure 3.1C). Those flies that survive to adulthood exhibit 
reduced longevity compared to the SCA3 flies that are not expressing exogenous Rad23 (Figure 
3.1G). 
Flies expressing exogenous Rad23 or expressing RNAi targeting Rad23 in the absence of 
ataxin-3 were kept as healthy stocks for over a year without clear signs of reduced fecundity or 
of toxicity (Figure 3.1E and data not shown). These collective data from the perturbation of 
Rad23  levels  support  the  idea  that  this  proteasome-associated  protein  regulates  pathogenic 
ataxin-3 levels and subsequent toxicity. These results led us to next investigate if disturbing the 
binding site of this protein on ataxin- 3 is beneficial in vivo. 
3.2.2 Mutating UbS2 reduces ataxin-3 protein levels, but greatly enhances its toxicity 
Based on the results from our experiments with altered Rad23 levels, we hypothesized 
that  reducing  binding  of  UbS2  to  Rad23  would  lower  Ataxin-3(SCA3)  protein  levels  and 
subsequently  alleviate  its  toxicity.  We  generated  additional  transgenic  flies  that  express 
Ataxin-3(SCA3) with a mutation in UbS2 that was previously shown by us and others to impair 
Rad23 binding (Blount et al., 2014; Nicastro et al., 2009; Nicastro et al., 2010), in this case by 
approximately 50 percent (Blount et al., 2014). This mutation (referred to as UbS2*Mild) replaces 
a  critical  tryptophan  residue  on  UbS2  with  an  alanine.  It  does  not  alter  ataxin-3’s  cellular 
distribution, or the overall structure of the isolated catalytic domain; it does not negate the ability 
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of the full-length protein to become ubiquitinated and catalytically activated; it does not abrogate 
the catalytic activity of full-length ataxin-3 ((Blount et al., 2014; Nicastro et al., 2010; Todi et al., 
2010) and data not shown); and, in the context of ataxin-3 with a normal polyQ repeat, this 
mutation does not impact fly longevity (Figure 3.2A). This mutation also does not perturb the 
ability  of  ataxin-3  to  bind  another  of  its  partners,  VCP/p97  (Figure  3.2B).  Together,  these 
findings led us to conclude that the conformation of the overall catalytic domain of ataxin-3 is 
Figure  3.2.  Mutating  UbS2  does  not  cause  toxicity  in  wild  type  ataxin-3,  impair  binding  of  ataxin-3  to  VCP/p97,  or  alter  the 
aggregation  propensity  of  ataxin-3  (Supplemental  to  Figure  3.3)  (A)  Adult  fly  longevity  from Drosophilae  ubiquitously  expressing 
Ataxin-3(WT)-UbS2*Mild compared to the same population of control flies that was depicted in Figure 3.1D. Ataxin-3(WT)-UbS2*Mild and 
control flies were aged independently. Ubiquitous expression of constructs was driven by the sqh-Gal4 driver. (B) Co-IP from HeLa cells 
expressing FLAG-tagged pathogenic ataxin-3 with UbS2 intact or mutated. (C) Western blot of soluble and insoluble fractions from whole, 
one-day-old adult flies expressing pathogenic ataxin-3 without or with a mild UbS2 mutation. Transgenes were pan-neuronally expressed 
under the control of the elav-Gal4 driver. Both the ataxin-3 band and smear were included in the quantification. (D) Western blot of soluble 
and insoluble fractions from whole cell  lysates expressing pathogenic ataxin-3 without or with a mild UbS2 mutation. HeLa cells were 
transfected with the indicated constructs and harvested 48 hours later. Transfection was conducted such that protein levels of Ataxin-3(SCA3)-
Intact and UbS2*Mild were comparable among the two groups. 
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not detrimentally impacted by the UbS2*Mild mutation.  
Surprisingly, we found that expression of UbS2*Mild throughout the fly causes lethality at 
early pupal stages (Figure 3.3A). Western blots from larval lysates demonstrated that mutating 
UbS2 reduces Ataxin-3(SCA3) protein levels (Figure 3.3B),  confirming our earlier  data that 
UbS2 is critical for ataxin-3 protein levels. Nevertheless, the lethality phenotype is markedly 
worse than what we observe in the flies expressing Ataxin-3(SCA3) with UbS2 intact, which 
reach pharate adult and adult stages (Figure 3.3A).  
Since these results failed to support our above hypothesis, we pan-neuronally expressed 
the Ataxin-3(SCA3) constructs to more thoroughly characterize the phenotype. Western blotting 
revealed  that  mutating  UbS2  leads  to  lower  Ataxin-3(SCA3)  protein  levels  (Figure  3.3D), 
similar  to  what  was observed with ubiquitous expression in larvae (Figure 3.3B).  qRT-PCR 
indicates that this is not due to differences at the mRNA level (Figure 3.3C).  To examine if 
mutating  UbS2  alters  the  aggregation  propensity  of  Ataxin-  3(SCA3)  before  the  onset  of 
pathology,  we  performed  differential  centrifugation  of  one-day-old  flies  pan-neuronally 
expressing Ataxin-3(SCA3)-Intact or UbS2*Mild. We did not observe a noticeable difference in 
soluble/insoluble fractions of Ataxin-3(SCA3)-Intact or UbS2*Mild in flies (Figure 3.2C), or in 
mammalian  cell  culture  (Figure  3.2D).  When  Ataxin-3(SCA3)-Intact  is  expressed  pan-
neuronally,  flies  exhibit  reduced  longevity  and  motility  (Figure  3.3E  and  F).  However, 
expression  of  UbS2*Mild  triggers  greater  impairment  in  longevity  and  motility  than 
Ataxin-3(SCA3)-Intact, supporting our results from ubiquitous expression of these two proteins 
(Figure 3.3A).  
Drosophila  eyes  are  a  popular  tool  for  investigating  neurodegenerative  diseases,  as 
degeneration can be reliably visualized at the external level or internally through histological 
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Figure 3.3. Mutating UbS2 of pathogenic ataxin-3 increases its toxicity. (A) Lethality observed when pathogenic ataxin-3 with or without a 
mild UbS2 mutation is ubiquitously expressed. (B) Western blots from larvae ubiquitously expressing pathogenic ataxin-3 with or without a 
UbS2 mutation. Expression of constructs in (A) and (B) was driven by the sqh-Gal4 driver. Means ± SD. Asterisks: P < 0.05 from Student’s t-
tests compared to line 1. Lines 1, 2, and A, B are from different founders, which had similar phenotypic outcomes and were combined in later 
studies. (C) qRT-PCR data from one-day-old flies pan-neuronally expressing pathogenic ataxin-3 with or with- out a mild UbS2 mutation. 
Endogenous control: rp49. Means ± SD. N.S: non-statistically significant. (D) Western blots from adult flies pan-neuronally expressing patho- 
genic ataxin-3 with or without a UbS2 mutation. Means ± SD. Asterisks: P < 0.05 from Student’s t-tests compared to line 1. Lines 1, 2, and A, 
B are from different founders,  which had similar phenotypic outcomes and were combined in later  studies.  (E)  Longevity of flies pan-
neuronally expressing pathogenic ataxin-3 with or without a mild UbS2 mutation. (F) Results from negative geotaxis motility assays, which 
were repeated at least three times, totaling at least 100 flies per genotype. Means ± SD. Asterisks: P < 0.05 from Student’s t-tests compared to 
Ctrl (black) or Intact (red) for each time point. Ctrl: empty vector inserted into site attP2. Expression of constructs in (C)–(F) was driven by 
the elav-Gal4 driver. 
 34
sectioning.  Using  the  GMR-Gal4  driver,  we  drove  the  expression  of  pathogenic  ataxin-3 
transgenes  in  Drosophila  eyes  to  characterize  the  subsequent  degeneration.  Once  again,  we 
witnessed a significant reduction in ataxin-3 protein in dissected fly heads expressing UbS2*Mild, 
as compared to ones expressing the intact variant (Figure 3.4A). Expressing Ataxin-3(SCA3)-
Intact in fly eyes leads to a slight depigmentation of the retina, which is visible by day 14 and 
increases  with  age  (Figure  3.4B).  On  day  14,  the  dark,  central  pseudo-pupil  is  also  lost, 
signifying  a  compromise  of  the  underlying  photoreceptor  cells.  In  the  fly  eyes  expressing 
UbS2*Mild,  depigmentation  and  loss  of  the  pseudo-pupil  is  observed  as  early  as  day  7  and 
progresses more markedly than with Ataxin-3(SCA3)-Intact (Figure 3.4B).  
Next,  we performed histology to  obtain  a  more  detailed  look at  the  structure  of  the 
internal eye. A healthy Drosophila eye is characterized by an organized ommatidial array with 
Figure 3.4. Mutating UbS2 increases pathogenicity of ataxin-3 in fly eyes. (A) Western blots from fly heads expressing pathogenic ataxin-3 
without or with a UbS2 mutation. Means ± SD. Asterisks: P < 0.05 from Student’s t-tests compared to line 1. Lines 1, 2, and A, B are from 
different founders, which had similar phenotypic outcomes and were combined in studies in the other panels of this figure. (B) External photos 
and (C) histological sections of fly eyes expressing pathogenic ataxin-3 without or with a mild UbS2 mutation. Ctrl: empty vector inserted into 
attP2. White circle in (B): example of the pseudo-pupil. Red boxes in (C): examples of densely-staining aggregates. The precise subcellular 
localization of the aggregates is not clear from this assay. Red bracketed lines in (C): examples of disruption of the ommatidial boundaries. 
Expression of constructs was driven by the GMR-Gal4 driver. 
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distinct boundaries between the ommatidia, the functional unit of the eye. With Ataxin-3(SCA3)-
Intact, a slight disruption of the ommatidial array is visible at day 7 (Figure 3.4C). By day 14, 
darkly  staining  structures,  which  were  shown previously  to  contain  the  pathogenic  ataxin-3 
protein  (Warrick  et  al.,  2005),  are  visible.  At  28  days,  the  ommatidial  array  is  significantly 
degenerated.  Compared  to  the  effect  of  Ataxin-3(SCA3)-Intact,  UbS2*Mild  causes  markedly 
increased disorganization of the ommatidial array and the presence of densely-staining structures 
as early as day 7. By day 28, the ommatidial boundaries are no longer distinguishable. The data 
from Figures  3.3  and  3.4  demonstrate  that  pathogenic  ataxin-3  with  mutated  UbS2  causes 
significantly more degeneration than intact Ataxin-3(SCA3) in various fly tissues.  
Our  working  model  predicted  that  reducing  Rad23  binding  to  Ataxin-3(SCA3)  by 
mutating  UbS2  would  decrease  Ataxin-3(SCA3)  protein  levels  and  lower  its  toxicity. 
Characterization of flies expressing Ataxin-3(SCA3)-Intact or Ataxin-3(SCA3)-UbS2*Mild under 
the control of different drivers revealed that mutating UbS2 reduces Ataxin-3(SCA3) protein 
levels, but greatly enhances the toxic phenotype. In the fly eyes, this toxicity is concomitant with 
the presence of densely-staining aggregates on an earlier time scale with UbS2*Mild than with 
Ataxin-3(SCA3)-Intact. The exact type of aggregated species formed by pathogenic ataxin-3 in 
vivo is likely to be dependent on cellular context and type of tissue. These results led us to next 
probe  how  disrupting  the  interaction  between  Ataxin-3(SCA3)  and  Rad23  increases  the 
pathogenicity of the Ataxin-3(SCA3) protein.  
3.2.3 Mutating UbS2 increases ataxin-3 toxicity by compromising its autoprotective function 
Wild-type ataxin-3 is protective in Drosophila  models of polyQ diseases (Burr et  al., 
2014; Tsou et al., 2013; Tsou et al., 2015b; Warrick et al., 2005). These findings were supported 
by  studies  in  mammalian  cell  culture  where  ataxin-3  also  protects  against  various  stressors 
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(Chatterjee  et  al.,  2015;  Reina  et  al.,  2012;  Reina  et  al.,  2010;  Zhou  et  al.,  2013a).  Work 
published by the Bonini lab (Warrick et al., 2005) and ours (Tsou et al., 2015b) reported that 
wild-type ataxin-3 requires both its catalytic activity and its binding to Rad23 to protect against 
polyQ-dependent toxicity in Drosophila. Collectively, these earlier results from flies presented 
the possibility that pathogenic ataxin-3 retains the protective function against itself (Figure 3.5A 
summarizes the model). We posited that when we mutate UbS2 to reduce Rad23 binding, we 
also compromise ataxin-3’s autoprotective function. Without its autoprotection, the UbS2*Mild 
protein  is  more  toxic  than  Ataxin-3(SCA3)-Intact,  even  though  there  is  less  protein  present 
(Figure 3.5A; also see Figure 3.8A).  
To first test whether mutating UbS2 impairs the protective function of Ataxin-3(SCA3), 
we co-expressed a  polyQ peptide  with  78 glutamine repeats  (polyQ78)  alongside  full-length, 
pathogenic ataxin-3 transgenes in Drosophila  eyes.  PolyQ78 is  the isolated C terminus of the 
ataxin-3 protein without UIMs or the N terminus (Warrick et al., 1998). Fly eyes expressing two 
copies of polyQ78 exhibit severe depigmentation of the retina (Figure 3.5B). Indentations are also 
visible on the external eye, indicative of the collapse of internal structures. Flies heterozygous for 
polyQ78 and the empty host vector for Ataxin-3(SCA3) transgenes display milder,  but clearly 
visible external depigmentation. Expression of wild-type ataxin-3 ameliorates this phenotype, as 
also shown previously  (Burr et al., 2014; Tsou et al., 2013; Tsou et al., 2015b; Warrick et al., 
2005). When Ataxin-3(SCA3)-Intact is co-expressed with polyQ78, the level of degeneration is 
significantly  less  than  what  is  observed  in  flies  expressing  two  polyQ78  alleles.  However, 
UbS2*Mild is  unable  to  suppress  polyQ78 toxicity,  supporting  the  notion  that  Ataxin-3(SCA3) 
retains some protective function, and that mutating UbS2 results in at least some loss of this role.  
To further examine the importance of an intact UbS2 on the pathogenicity of the SCA3 
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protein, we generated additional transgenic fly lines that express catalytically inactive, patho- 
genic ataxin-3 either with all of its domains intact (Ataxin- 3(SCA3)*C14A -Intact) or with UbS2 
mutated  (Ataxin-3(SCA3)*C14A-UbS2*Mild)  (Figure  3.1B).  To  render  Ataxin-3(SCA3) 
Figure 3.5. Mutating UbS2 of catalytically inactive, pathogenic ataxin-3 reduces its protein levels and toxicity. (A) Table summarizing 
the working model for the role of ataxin-3’s UbS2 in toxicity. (B) Photos of external eyes expressing a truncated polyQ fragment of ataxin-3 
with 78 repeats and co-expressing the indicated lines. Flies were heterozygous for all transgenes, except for flies homozygous for polyQ78 (far 
left). Constructs were expressed using the GMR-Gal4 driver. White arrows: examples of indentation. (C) Western blots from adult flies pan-
neuronally expressing pathogenic ataxin-3 that is catalytically active or inactive. Means ± SD. Black asterisks: P < 0.05 from Student’s t-tests 
compared to catalytically active ataxin-3 line 1. Red asterisks: P < 0.05 from Student’s t-tests compared to catalytically inactive ataxin- 3 line 
1. Lines 1, 2, and A, B are from different founders, which had similar phenotypic outcomes and were combined in later studies in this figure. 
(D)  qRT-PCR data  from one-day-old flies  expressing pathogenic,  catalytically  inactive ataxin-3 with or  without  a  mild UbS2 mutation. 
Endogenous control: rp49. Means ± SD. N.S: non-statistically significant. (E) Longevity data from flies expressing pathogenic, catalytically 
inactive ataxin-3 without or with a mild UbS2 mutation. (F) Motility of flies expressing pathogenic, catalytically inactive ataxin-3 without or 
with a mild UbS2 mutation. Flies were 7 days old. N = 10, totaling at least 100 flies per genotype. Asterisk: P < 0.05 from Student’s t-tests 
compared to C14A-Intact. 
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catalytically inactive, we mutated the critical cysteine in its protease domain to an alanine, which 
compromises the protein’s ability to protect against polyQ toxicity (Todi et al., 2007; Todi et al., 
2010; Tsou et al., 2013; Winborn et al., 2008). These transgenic lines would help us to determine 
if mutating UbS2 mitigates ataxin-3-dependent toxicity when its autoprotective role is no longer 
a factor.  
When these catalytically inactive transgenes are pan-neuronally expressed in Drosophila, 
the C14A-UbS2*Mild mutation reduces ataxin-3 protein levels, independently of transcriptional 
levels (Figure 3.5C and D). The protein levels of catalytically inactive Ataxin-3(SCA3) are also 
significantly lower than catalytically active Ataxin-3(SCA3), indicating that ataxin-3’s catalytic 
activity regulates its steady state levels in vivo. Importantly, flies expressing C14A-UbS2*Mild 
exhibit improved adult longevity compared to the flies with C14A-Intact (Figure 3.5E). Motility 
is also significantly improved in C14A-UbS2*Mild flies on day 7 (Figure 3.5F).  
Overall, these results indicate that reducing ataxin-3 protein levels can indeed decrease 
the toxicity of pathogenic ataxin-3, as long as its protective function is not a factor. We conclude 
that UbS2*Mild increased the toxicity of Ataxin-3(SCA3) in our earlier experiments because the 
mutation impaired its autoprotective function.  
3.2.4 Strong disruption of pathogenic ataxin-3’s UbS2 is less toxic than mild disruption  
Mild disruption of Rad23 binding to UbS2, which decreases binding of ataxin-3 to Rad23 
in vitro by about 50% (Blount et al., 2014), yielded a more toxic protein. We next reasoned that a 
stronger  disruption of  Rad23 binding to  UbS2 might  reduce the protein’s  toxicity  by nearly 
eliminating the ataxin-3 protein. To test this possibility, we mutated three amino acid residues of 
UbS2  to  glutamic  acid  (Ataxin-3(SCA3)-UbS2*Strong;  Figure  3.1B).  In  vitro  binding  assays 
indicate  that  UbS2*Strong greatly  reduces  binding to  Rad23 (Figure 3.6A).  When we express 
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pathogenic  ataxin-3  with  the  UbS2*Strong  mutation  in  HeLa  cells,  we  notice  a  reduction  in 
Ataxin-3(SCA3) levels more profound than with UbS2*Mild (Figure 3.6B). The turnover rate of 
Figure 3.6. A stronger mutation of UbS2 reduces pathogenic ataxin-3 protein levels and toxicity compared to UbS2*Mild. (A) Western 
blot from in vitro binding assays of Ataxin-3(WT) and full-length, GST-tagged Rad23A. GST or GST-Rad23 were pulled down on glutathione 
agarose beads, washed thrice with NETN and incubated with Ataxin-3(WT)-Intact or Ataxin-3(WT)-UbS2*Strong for 1h on ice. Colored arrows 
denote the different amounts of ataxin-3.  Percentages compare UbS2-mutated ataxin-3 pulled down by GST-Rad23A to its  non-mutated 
counterpart of the same amount. (B) Western blots from whole cell lysates. HeLa cells were transfected with the indicated constructs and 
harvested 24h later.  Means ± SD. Asterisks: P < 0.05 from Student’s t-tests when compared to Intact (black) or UbS2*Mild (purple). (C) 
Western blots from HeLa cells transfected with the indicated constructs and treated 24h later with cycloheximide (CHX) for the indicated 
amounts of time. Transfection and loading were done such that the protein level of the two different versions of ataxin-3 were comparable at 
0h. Example shown is from experiment repeated independently at least 4 times with similar results. (D) Lethality observed when ubiquitously 
expressing pathogenic ataxin-3 without or with a UbS2 mutation. (E) Western blots from larvae ubiquitously expressing pathogenic ataxin-3 
without or with a strong UbS2 mutation. Means ± SD. Asterisks: P < 0.05 from Student’s t-test compared to Intact. Lines 1 and 2 are from 
different  founders,  which  had  similar  phenotypic  outcomes  and  were  combined  in  phenotypic  studies.  (F)  qRT-PCR data  from larvae 
ubiquitously  expressing  pathogenic  ataxin-3  without  or  with  a  strong  UbS2  mutation.  Endogenous  control:  rp49.  N.S:  non-statistically 
significant. (G) Longevity of flies pan-neuronally expressing pathogenic ataxin-3 without or with a UbS2 mutation. (H) Results from motility 
assays of flies expressing pathogenic ataxin-3 without or with a UbS2 mutation. Means ± SD. Asterisks: P < 0.05 from Student’s t-tests 
compared to Intact (red) or UbS2*Mild (purple). N=10, totaling at least 100 flies per genotype. 
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UbS2*Strong is also higher than that of UbS2*Mild (Figure 3.6C).  
We generated additional fly lines that express pathogenic ataxin-3 with the UbS2*Strong 
mutation. Ubiquitous expression of UbS2*Strong elicits developmental lethality primarily in the 
mid pupal stage, which represents a slight improvement from what was seen earlier with the 
UbS2*Mild  flies  (Figure 3.6D).  Western blotting of  larvae expressing UbS2*Strong reveals  that 
ataxin-3 protein levels are reduced by approximately 90% (Figure 3.6E). qRT-PCR indicates that 
the decrease in the UbS2*Strong version is not due to transcriptional changes (Figure 3.6F).  
We  continued  our  analyses  of  the  SCA3  phenotype  by  pan-neuronally  expressing 
UbS2*Strong. When expressed in neurons, the protein levels of this version of ataxin-3 are also 
markedly  lower  than  those  of  the  intact  counterpart  (data  not  shown),  similar  to  what  was 
observed with ubiquitous expression in larval lysates (Figure 3.6E). These adults live longer and 
perform better in the motility assay than the flies expressing UbS2*Mild (Figure 3.6G and H). 
Still,  in  general  they  do  not  perform  as  well  as  flies  expressing  Ataxin-3(SCA3)-Intact. 
Collectively, these data further support the role of UbS2 in the pathogenicity of ataxin-3, and 
stress the importance of this site on both the toxicity and protein levels of the SCA3 protein.  
3.2.5 DnaJ-1 suppresses toxicity from Ataxin-3(SCA3) with mutated UbS2  
Previously,  we  reported  that  wild-type  ataxin-3  (denoted  here  as  Ataxin-3(WT)) 
suppresses  polyQ  toxicity  in  Drosophila  by  binding  Rad23  and  leading  to  an  increase  in 
endogenous DnaJ-1 at mRNA and protein levels (Tsou et al., 2015b). A version of ataxin-3 with 
the UbS2*Mild mutation did not have the same effect on DnaJ-1 (Tsou et al., 2015b). DnaJ-1 is a 
member of the J/HSP40 family of co-chaperone proteins that maintain the substrate specificity 
and stimulate the ATPase activity of HSP70 chaperones (Kampinga and Craig, 2010; Koutras 
and Braun, 2014). Since our data are consistent with the idea that Ataxin-3(SCA3) with mutated 
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UbS2 is more pathogenic due to impaired autoprotection, we tested whether DnaJ-1 can suppress 
this toxicity.  
When we co-express DnaJ-1 with UbS2*Mild in fly eyes, we observe great improvement in 
the internal retinal structure: the boundaries and the organization of the ommatidia are restored 
(Figure 3.7A).  External photos of DnaJ-1 eyes display the reappearance of the pseudo-pupil, 
consistent with a healthy underlying structure (Figure 3.7A). Pan-neuronal expression of DnaJ-1 
alongside UbS2*Mild  also improves adult longevity and motility (Figure 3.7B and C). Moreover, 
exogenous DnaJ-1 reduces the rate of developmental lethality in UbS2*Mild flies when the toxic 
protein is expressed everywhere (Figure 3.7D). Instead of dying in the early pupal stage, these 
Figure 3.7. Exogenous DnaJ-1 suppresses toxicity from pathogenic ataxin-3 with mutated UbS2. (A) External eye photos and histological 
sections of fly eyes expressing pathogenic ataxin-3 with a mild UbS2 mutation in the absence or presence of exogenous DnaJ-1. Constructs 
were expressed using the GMR-Gal4 driver. Vector Ctrl: empty vector inserted into attP2. Red boxes: examples of densely-staining structures. 
Red bracketed line: an example of disruption of the ommatidial boundaries. (B) Motility of flies expressing pathogenic ataxin-3 with a mild 
UbS2 mutation in the presence or absence of exogenous DnaJ-1. Here, elav-Gal4 was on the third chromosome, expressing at lower levels 
than in previous figures, where elav-Gal4 was on the X chromosome. Means ± SD. Asterisks: P < 0.05 from Student’s t-test, compared to 
UbS2*Mild without exogenous DnaJ-1. N=10, totaling at least 100 flies per genotype. (C) Longevity of flies expressing pathogenic ataxin-3 
with a mild UbS2 mutation in the presence or absence of exogenous DnaJ-1. (D) Lethality observed when ubiquitously expressing pathogenic 
ataxin-3 with a mild UbS2 mutation in the presence or absence of exogenous DnaJ-1, or wild type ataxin-3, or knockdown of DnaJ-1 through 
UAS-RNAi. 
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flies exhibit late pupal and pharate adult lethality. A small number of adults even successfully 
eclose and survive for two or three days. Importantly, RNAi-dependent knockdown of DnaJ-1 
causes the UbS2*Mild  flies to die much earlier (Figure 3.7D).  
Lastly, we examined the protective role of Ataxin-3(WT) against its pathogenic variant 
with UbS2 mutated. As summarized in Figure 3.7D, expression of non-pathogenic ataxin-3 has a 
suppressive  effect  towards  UbS2*Mild that  closely  mirrors  the  protective  effect  of  exogenous 
DnaJ-1. Ataxin-3(WT) delays lethality from pathogenic ataxin-3 with a mutated Rad23-binding 
site  from early pupal  to late  pupal  and pharate adult  stages.  A handful  of  adults  eclose and 
survive  for  a  few days.  Altogether,  the  results  in  Figure  3.7  lend  additional  support  to  the 
hypothesis that pathogenic ataxin-3 with mutated UbS2 is more toxic due to a perturbation of its 
autoprotective role.  
Wild-type ataxin-3 has a protective effect against various polyQ proteins in Drosophila 
(Burr  et  al.,  2014;  Tsou et  al.,  2013;  Tsou et  al.,  2015b;  Warrick et  al.,  2005).  This  role  of 
ataxin-3 in the fly depends on its catalytic activity, on an intact UbS2, and on the presence of 
Rad23 (Tsou et  al.,  2015b; Warrick et  al.,  2005).  According to those findings,  ataxin-3, in a 
manner dependent on Rad23, leads to an increase in the transcription of DnaJ-1 and a subsequent 
rise in its protein levels. This co-chaperone then functions with inducible heat shock proteins to 
reduce the aggregation and toxicity of polyQ species in flies. The data in Figure 3.7, together 
with the results from prior figures where we perturbed Rad23 levels, mutated UbS2 of ataxin-3, 
and  incapacitated  the  DUB  activity  of  pathogenic  ataxin-3,  collectively  indicate  a  similar 
mechanism at work on autoprotection from pathogenic ataxin-3.  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3.3 Discussion  
Our  prior  work  showed  a  critical  role  for  the  SCA3  protein  interaction  with  the 
proteasome-associated protein,  Rad23 in the proteasomal turnover of  ataxin-3 (Blount  et  al., 
2014). Whether the site of this interaction was directly important for the toxicity of the SCA3 
protein, or if targeting this interaction could be beneficial against SCA3, was unclear. We found 
that mutating UbS2 on ataxin-3 to disrupt this interaction substantially reduces steady state levels 
of the SCA3 protein in vivo, but greatly enhances its toxicity. According to our work, ataxin-3’s 
binding  to  Rad23  regulates  this  polyQ  protein’s  levels,  autoprotective  function,  and, 
consequently, its pathogenicity. The data presented here showcase a previously unreported role 
Figure 3.8. Model of Rad23 and UbS2 regulating ataxin-3’s levels and toxicity. (A) Knocking down Rad23 reduces its availability to bind 
ataxin-3 at UbS2, increasing ataxin-3’s degradation. This reduces ataxin-3 protein levels while leaving its autoprotection intact, resulting in 
lowered ataxin-3 toxicity. (B) Ataxin-3 with intact UbS2 is present at baseline levels; its pathogenicity is regulated by its autoprotection, which 
requires  Rad23  binding  to  UbS2.  (C)  Exogenous  Rad23  increases  its  availability  to  bind  ataxin-3,  inhibiting  ataxin-3’s  proteasomal 
degradation and increasing its toxicity. (D) Mutating UbS2 reduces Rad23 binding, resulting in lower ataxin-3 levels. However, mutating this 
site compromises ataxin-3’s protection against itself, thus increasing its toxicity. 
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for  the  interaction  between  the  SCA3  protein  and  Rad23  as  a  regulator  of  ataxin-3’s  own 
pathogenicity  in  an  intact,  model  organism  (Figure  3.8).  Our  results  bring  together  a  new 
understanding of the role of ataxin- 3’s domains and its interactions with partners in its toxicity. 
They also highlight the importance of protein context in the biology of this polyQ disease, and 
the need to carefully consider it when devising strategies for suppressive avenues.  
Ataxin-3 can also bind ubiquitin through UbS2 (Nicastro et al.,  2009; Nicastro et al., 
2010). One might surmise that binding of ubiquitin, or other similar proteins, could potentially 
impact  ataxin-3 levels  and toxicity through their  interaction with UbS2.  In earlier  work,  we 
found that knockdown of ubiquitin-like proteins did not impact ataxin-3 levels in Drosophila 
(Blount  et  al.,  2014).  Our genetic  manipulations of  Rad23 levels  in this  study and in other, 
previously published work (Blount et al., 2014) make a strong case for a specific and significant 
role from the binding of ataxin-3 to Rad23 in the toxicity and levels of the SCA3 protein.  
Ataxin-3’s  interaction  with  Rad23  might  have  a  cellular  role  by  assisting  with  the 
degradation of select poly-ubiquitinated substrates destined for the proteasome ((Buchberger et 
al., 2010; Dantuma et al., 2009). Binding of ataxin-3 to Rad23 hinders the degradation of the 
SCA3 protein (Blount et al., 2014). This interaction between Rad23 and ataxin-3, however, need 
not impact the ability of these two ubiquitin-binding proteins to deliver cargo to the degradative 
machinery, which depends on the transfer of poly-ubiquitinated substrates from shuttles to the 
19S component of the proteasome (Ristic et al., 2014).  
Our findings raise the question why we observe decreased ataxin-3-dependent toxicity 
when we reduce Rad23 levels through RNAi, but not when we mutate UbS2 to reduce Rad23 
binding to ataxin-3. Rad23 knockdown reduces its levels and thus ataxin-3 protein levels as a 
result of its increased degradation (Figure 3.1A; (Blount et al., 2014)), but the remaining Rad23 
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and ataxin-3 proteins can still interact since UbS2 is intact. In this scenario, ataxin-3 is likely less 
toxic because some of the pathogenic protein is eliminated, but the remaining SCA3 protein can 
still bind Rad23 and exert its unperturbed autoprotective role. When we mutate UbS2, we reduce 
the protective ability of all of the ataxin-3 protein present as a result of compromised binding to 
Rad23 (Figure 3.8).  Ataxin-3 with mutated UbS2 is  unable to elevate expression of the co-
chaperone DnaJ-1 (Tsou et al., 2015b). Thus, it is not surprising that when we increase the levels 
of DnaJ-1, we observe a reduction in the pathogenicity of ataxin-3 with mutated UbS2.  
Various  studies  have  reported  that  reducing  levels  of  disease  proteins  improves  the 
pathology in SCA3 and other polyQ disorders (Alves et al., 2010; Harper et al., 2005; Pedersen 
and Heegaard, 2013; Tsou et al., 2011; Williams et al., 2009; Williams and Paulson, 2008; Xia et 
al., 2004). Our work demonstrates that the means by which pathogenic protein levels are reduced 
can  influence  its  toxicity.  Since  UbS2  is  important  for  both  ataxin-3’s  protein  levels  and 
autoprotective  function,  genetically  mutating  this  site  to  prevent  Rad23  binding  proved 
inadequate for simultaneously reducing ataxin-3 levels and its toxicity. Thus, pathogenic protein 
levels cannot be reduced indiscriminately; the functionality of the protein binding domains and 
its interactions must be considered before targeting it therapeutically.  
Our  results  show  that  mutating  UbS2  exacerbates,  rather  than  alleviates,  ataxin-3-
dependent  toxicity  in  Drosophila.  The  question  remains  whether  UbS2 could  be  a  potential 
therapeutic target for SCA3 in mammalian systems. The toxicity from mutating UbS2 in flies 
results from disruption of ataxin-3’s protective role. While a protective role for ataxin-3 in flies 
and mammalian cells is clear (Burr et al., 2014; Chatterjee et al., 2015; Reina et al., 2012; Reina 
et al., 2010; Tsou et al., 2013; Tsou et al., 2015b; Warrick et al., 2005; Zhou et al., 2013a), there 
is conflicting evidence for a similar role for ataxin-3 in mice. In one study, SCA3 transgenic mice 
 46
that were heterozygous for pathogenic ataxin-3 and possessed one copy of wild-type ataxin-3 
exhibited a  milder  phenotype than mice expressing pathogenic  ataxin-3 alone (Cemal  et  al., 
2002) Alternatively, co-expression of wild-type ataxin-3 in a different SCA3 mouse model did 
not  ameliorate  the  phenotype  (Hubener  and  Riess,  2010).  Yet  another  study  reported  that 
complete  loss  of  endogenous,  wild-type  ataxin-3  in  a  mouse  model  of  Huntington’s  disease 
exacerbated a motor phenotype, but it did not affect other aspects of the pathology (Zeng et al., 
2013). If ataxin-3 does not play a significant protective role in intact mammals, mutating UbS2 
in situ could be a potential therapeutic approach for SCA3, as this should reduce ataxin-3 protein 
levels  without  causing  much  additional  toxicity.  Since  ataxin-3’s  neuroprotective  role  in 
mammals remains to be fully clarified,  our work suggests that  the ideal  approach for SCA3 
therapy should aim to reduce ataxin-3 levels while leaving its autoprotection intact.  
In conclusion, the interaction of ataxin-3 with Rad23 through the UbS2 domain appears 
to  serve  dual  roles  on  the  SCA3 protein  by  regulating  its  levels  and  inherent  toxicity.  Our 
findings provide novel clues towards the understanding of the biology of disease in SCA3, and 
caution against arbitrarily reducing the levels of a toxic protein for the purposes of therapy. The 
next chapter will investigate the interaction of ataxin-3 with another one of its binding partners, 
VCP. 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CHAPTER 4: Toxicity and aggregation of the polyglutamine disease protein, ataxin-3, is 
regulated by its binding to VCP/p97 in Drosophila melanogaster 
 
Under review: Ristic G*, Sutton JR*, Libohova K, Todi SV (2018). Toxicity and aggregation of 
the polyglutamine disease protein, ataxin-3 is regulated by its binding to VCP/p97 in Drosophila 
melanogaster. Neurobiology of Disease. *- these authors contributed equally to this manuscript.  
4.1 Introduction  
The previous chapter explored ataxin-3's interaction with Rad23, an interaction partner 
that is linked to ataxin-3’s neuroprotective function. Another protein quality control partner of 
ataxin-3  is  Valosin-Containing  Protein  (VCP,  also  known  as  p97),  a  member  of  the  AAA 
(ATPases Associated with diverse cellular Activities) family of proteins (Figure 4.1A-B) (Meyer 
et al., 2012). VCP functions as a homo-hexamer, converting chemical energy harvested from ATP 
hydrolysis to mechanical energy to exert force on its substrates. It is an essential, ubiquitously 
expressed protein involved in numerous cellular processes, including protein degradation (Xia et 
al., 2016).  
Ataxin-3 binds VCP directly (Doss-Pepe et al., 2003; Hirabayashi et al., 2001; Wang et 
al.,  2006)  through  a  region  on  its  C-terminal  half  (Figure  4.1A)  (Boeddrich  et  al.,  2006). 
According to biochemical and cell-based experiments from an elegant study by the Wanker and 
Bonini  labs,  ataxin-3  binds  to  the  N-terminal  portion  of  VCP through an  arginine-rich  area 
(amino acid sequence RKRR) (Boeddrich et al., 2006) (Figure 4.1A). Mutating the VCP-binding 
site on ataxin-3 disrupts the interaction between these two proteins (Boeddrich et al., 2006). The 
same study also reported that VCP stimulates fibrillogenesis/aggregation of pathogenic ataxin-3 
in a dose-dependent manner in in vitro, reconstituted systems. These results suggested a seeding 
role  for  VCP:  the  hexamer  binds  multiple  ataxin-3  proteins,  increasing  their  chances  of 
interacting together and enhancing their initial aggregation (Boeddrich et al., 2006). Exogenous 
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VCP mitigated, to some extent, degeneration caused by full-length, pathogenic ataxin-3 in one 
tissue tested: the eyes of fruit flies (Boeddrich et al., 2006). These compelling data highlight the 
need for additional examinations to understand the interaction between ataxin-3 and VCP in vivo. 
Direct comparison between pathogenic ataxin-3 that can bind VCP and a version that has the 
VCP-binding site mutated—expressed similarly in various tissues— is necessary to appreciate 
the interplay between these proteins in SCA3. It would also help overall understanding of SCA3 
biology to examine if VCP regulates the aggregative propensity of pathogenic ataxin-3 in an 
intact animal, beyond in vitro settings. Lastly, examining the relationship of the VCP-ataxin-3 
interaction to the temporal aggregation and pathogenicity of the SCA3 protein in an intact animal 
would be helpful both to further our knowledge of SCA3 disease mechanisms and to examine if 
this interaction could be of therapeutic benefit. These were the various aspects that we set out to 
tackle in this work, by using Drosophila as a model organism.  
To accomplish this, we generated isogenic lines of Drosophila melanogaster that express, 
in a Gal4-UAS-dependent manner (Brand et al., 1994; Brand and Perrimon, 1993), full-length, 
human,  pathogenic  ataxin-3  with  a  normal  or  mutated  VCP-binding  site.  We  found  that 
pathogenic ataxin-3 with a mutated VCP-binding site is markedly less toxic in flies, even though 
the protein is present at levels similar to its VCP-binding counterpart. Initially, flies that express 
the SCA3 protein with impaired VCP-binding are indistinguishable from controls that do not 
express  any  pathogenic  ataxin-3.  This  coincides  with  markedly  lower  levels  of  aggregated 
ataxin-3 species. Altering the levels of endogenous VCP protein modulates the toxicity of the 
SCA3 protein in a manner that supports the idea of a nucleation role for the aggregation of 
ataxin-3 by this AAA ATPase. Our data highlight an important physiological role for VCP on 
ataxin-3-dependent degeneration and underscore the importance of non-polyQ regions of this 
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DUB to the toxicity of its expanded repeat.  
4.2 Results  
4.2.1 Mutating the VCP-binding site of ataxin-3 disrupts its interaction with VCP in flies  
We began our journey into the role of the VCP-ataxin-3 interaction in SCA3-like degen- 
eration in Drosophila by confirming that the VCP-binding site mutation, “RKRR” to “HNHH", 
disrupts the DUB’s interaction with fly VCP. This mutation was shown before to disrupt binding 
of recombinant ataxin-3 to mammalian VCP (Boeddrich et al., 2006). We generated recombinant, 
pathogenic ataxin-3 with 80 polyQ in bacterial cells.  This repeat is within patient range. We 
produced two versions of the DUB: one that has the intact VCP-binding site and one whose site 
is mutated from “RKRR” to "HNHH". We then incubated bead-bound, GST-tagged, recombinant 
ataxin-3 with whole fly lysates and probed for the ability of human ataxin-3 to interact with fly 
VCP. As shown in Figure 4.1C,  the pathogenic version of  ataxin-3 co-precipitates  fly VCP, 
whereas the version with impaired VCP-binding has a drastically reduced capacity to bind fly 
VCP; the western blot signal was barely above non-specific background that was non-specifically 
brought down by GST alone (Figure 4.1C).  This disruption in interaction between VCP and 
ataxin- 3 is similar to what we observe in mammalian cells: pathogenic ataxin-3 with impaired 
VCP-binding  is  unable  to  co-IP endogenous,  human  VCP beyond  non-specific  background, 
whereas pathogenic ataxin-3 with intact VCP-binding co-IPs this interactor (Figure 4.1D). In 
Figures 4.1C and D, we used mild conditions that brought down some VCP non-specifically, 
which helped us to not exclude the possibility of residual VCP interaction with VCP-binding-
mutated ataxin-3.  We did not  observe clear  and specific interaction of VCP with pathogenic 
ataxin-3 that has its VCP-binding site mutated. Lastly, as shown in Figure 4.1E, mutating the 
RKRR region on pathogenic ataxin-3 removes its ability to bind fly VCP in vivo. In this last 
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Figure 4.1. Pathogenic ataxin-3 with a mutated VCP-binding site does not bind Drosophila VCP. (A) Diagrammatic representation of 
ataxin-3. The catalytic domain of ataxin-3, Josephin Domain, is located at the structured N-terminal half of the protein. The inherently un- 
structured C-terminal portion contains three Ubiquitin Interacting Motifs (UIMs), the polyQ tract (which is abnormally expanded in SCA3 
patients), and the VCP-binding site. Box shows this site was mutated from “RKRR” to “HNHH” to disrupt the interaction with VCP. (B) 
Diagrammatic representation of VCP. VCP functions as a homohexamer. Each VCP protein contains an N-terminal domain (through which it 
binds to most of its co-factors, including ataxin-3), two tandem ATPase domains, and a short C-terminal tail. (C) Western blot from in vitro 
pulldowns with whole fly lysates and immobilized, recombinant GST, GST-Ataxin-3(SCA3)-Intact, or GST-Ataxin-3(SCA3)-HNHH. Both 
Ataxin-3(SCA3) constructs contained 80 polyQ repeats. Blots are representative of experiments repeated independently three times with the 
same outcomes. (D) Western blot of co-immunoprecipitations from HEK293 cells transiently transfected with the indicated constructs. Blots 
are representative of experiments repeated independently three times with the same outcomes. NS=Nonspecific band we often observe with 
the  polyclonal  ataxin-3  antibody.  (E)  Western  blot  of  co-immunoprecipitations  from dissected  heads  of  transgenic  flies  expressing  the 
indicated constructs. Transgenes were expressed through the eye-specific GMR-Gal4 driver. Blots are representative of experiment repeated 
independently three times with the same outcomes. In this panel and the rest  of the figures,  flies were heterozygous for all  drivers and 
transgenes, unless otherwise noted. (F) qRT-PCR results from whole adult flies expressing pathogenic ataxin-3 with an intact or mutated VCP-
binding site. Ataxin-3(SCA3)-Intact or Ataxin-3(SCA3)-HNHH was driven by the sqh-Gal4 ubiquitous driver. No significant differences in the 
mRNA expression levels were observed when the VCP-binding site is mutated to HNHH. N=4 independent repeats. In this panel and the rest 
of the figures, HNHH 1 and 2 are independently derived transgenic lines. Endogenous control: rp49. Means ± SD. P values were calculated by 
two-tailed Student’s t-tests, comparing HNHH 1 and HNHH 2 to Intact. (G) Western blot of fly lysates after cytoplasmic/nuclear centrifugal 
fractionation. Transgenic adult flies expressed pathogenic ataxin-3 with or without the VCP-binding site mutated from “RKRR” to “HNHH”. 
Ataxin-3(SCA3)-Intact  or  Ataxin-3(SCA3)-HNHH were  expressed  under  the  control  of  the  sqh-Gal4  driver.  “Intact  Control”  flies  were 
Ataxin-3(SCA3)-Intact-encoding flies without a driver. Asterisks: ubiquitinated ataxin-3. NS=Nonspecific band. Blots are representative of 
experiments repeated independently three times with the same outcomes. 
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setup, we co-expressed HA-tagged, fly VCP alongside ataxin-3 in fly eyes and precipitated VCP. 
HA-tagged, Drosophila VCP is able to co-IP pathogenic ataxin-3 with an intact VCP-binding 
site, but not the pathogenic version with the “RKRR to HNHH" mutation (Figure 4.1E). We 
conclude that this specific mutation on pathogenic ataxin-3 effectively disrupts the interaction of 
the SCA3 protein with Drosophila VCP.  
4.2.2 Mutating the VCP-binding site of ataxin-3 does not alter its protein or mRNA levels, or 
its subcellular localization  
At hand, we have flies that express pathogenic ataxin-3 with an intact or mutated VCP-
binding site. We generated the full-length, human, pathogenic ataxin-3 for earlier work (Chapter 
3). For the present work, we created new transgenic Drosophila lines expressing ataxin-3 with 80 
polyQ repeats  with  the  “RKRR” to  “HNHH" mutation.  The  new lines  were  constructed  by 
cloning this ataxin-3 transgene into the pWalium10-moe vector, which was used with the phiC31 
site-specific integrase system to insert the construct at the attP2 site on the third chromosome of 
the fly (Groth et al., 2004; Tsou et al., 2016). These flies are referred to as "HNHH" 1 and 2, as 
we utilized two independently-derived lines, which ultimately led to the same results that were 
combined  in  most  figures.  The  “HNHH"  lines  are  isogenic  to  the  “Intact”  SCA3  line;  the 
constructs are each inserted into attP2, in the same orientation and as a single copy (Groth et al., 
2004).  
First, we wanted to confirm that any difference in phenotype we might observe among 
the different lines is not due to a change in ataxin-3 transgene expression levels. We examined 
mRNA expression levels of ataxin-3 by qRT-PCR when the protein was expressed in the whole 
fly  using  the  ubiquitous  driver  sqh-Gal4  (Figure  4.1F).  The  "HNHH"-1  and  -2  lines  were 
compared to the line expressing pathogenic ataxin-3 with an intact VCP-binding site. There is no 
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statistically significant difference in the expression levels of ataxin-3 among the three fly lines. 
Our lab also showed previously that ataxin-3 turnover is not affected when the VCP-binding site 
was mutated in mammalian cells (Blount et al., 2014) or in Drosophila (Tsou et al., 2015b).  
The VCP-binding site on ataxin-3 is an arginine-rich region located at the C-terminus of 
ataxin-3. Previously, this domain was thought to encode a nuclear localization signal (Albrecht et 
al.,  2004).  We  examined  whether  mutating  the  VCP-binding  site  affects  the  localization  of 
pathogenic  ataxin-3  in  the  fly.  We  used  centrifugal  fractionation  to  enrich  cytoplasmic  and 
nuclear proteins from whole fly lysates when pathogenic ataxin-3 expression is driven by the 
ubiquitous  driver,  sqh-Gal4.  After  analysis  by  western  blotting  and  probing  with  ataxin-3 
antibody, we observed no difference in protein distribution between the cytoplasm and nucleus 
when the VCP-binding site  is  mutated (Figure 4.1G).  We conclude that  mutating the VCP-
binding site from “RKRR” to "HNHH" does not impact the cellular localization of pathogenic 
ataxin-3 in the fly.  
4.2.3 Mutating the VCP-binding site of pathogenic ataxin-3 reduces its toxicity in Drosophila  
To physiologically  assess  how mutating  the  VCP-binding  site  affects  the  toxicity  of 
ataxin-3 in Drosophila, we conducted longevity studies. As we reported previously (Chapter 3), 
pathogenic ataxin-3 is highly toxic to the fly when it is expressed ubiquitously. We observe death 
during late  pharate  adult  stages,  during eclosion from the pupal  case,  and shortly  following 
eclosion (Figure 4.2A). Those flies that successfully eclose survive for about 30 days (Figure 
4.2B); as a frame of reference, flies not expressing pathogenic ataxin-3 can live up to ~90 days 
(Chapter 3). "HNHH" mutant flies all reached adulthood (Figure 4.2A). We did not observe 
death during development as we had with flies encoding ataxin-3 with the intact VCP-binding 
site. From longevity data (Figure 4.2B), we observed a clear separation in the rates of death 
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early on: the "HNHH" mutant-expressing flies appear healthier and more flies remain alive in the 
earlier days of life than their “Intact” ataxin-3-expressing counterparts (Figure 4.2B). Whereas 
Figure 4.2. Mutating the VCP-binding site of pathogenic ataxin-3 delays its aggregation and toxicity when expressed in all fly tissues. In 
all panels, transgenes were expressed using the ubiquitous sqh-Gal4 driver. (A) Summary of effects on fly development and longevity when 
pathogenic  ataxin-3  with  an  intact  or  mutated  VCP-binding  site  is  expressed  in  all  fly  tissues.  (B)  Longevity  of  adult  flies  ubiquitously 
expressing pathogenic ataxin-3 with or without the VCP-binding site mutated from RKRR to HNHH. Control flies contained the sqh-Gal4 driver 
and the empty cloning vector (pWalium10-moe) inserted at the attP2 site, without an ataxin-3 transgene. Control flies lived up to ~90 days. (C, 
D) Western blots from one-day-old flies (C) or flies of different ages (D) expressing pathogenic ataxin-3 with or without a mutation in the VCP-
binding site. HNHH 1 and 2 are independently derived transgenic lines. Results are representative of experiments repeated independently at least 
three times with the same outcomes. In (C-E), and the rest of the figures in this manuscript, dotted lines help to visually categorize ataxin-3 
species into SDS-soluble and SDS-resistant. Asterisks: ubiquitinated ataxin-3. (E) Western blot from differential centrifugation of fly lysates into 
soluble supernatant and insoluble pellet fractions. Lysates are from 1-, 7-, or 14-day-old flies ubiquitously expressing pathogenic ataxin-3 with 
or without a mutated VCP-binding site. Ten μg of supernatant and 7 μl of pellet fractions were electrophoresed on 4-20% gradient gels. Results 
are representative of experiments repeated independently at least three times with the same outcomes. 
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about  25% of  flies  that  express  Ataxin-3(SCA3)-Intact  are  dead  before  day  5,  25% of  flies 
expressing the “HNHH" counterparts are dead by day 17. As more flies die, we observe that 
about 50% of flies expressing “Intact” pathogenic ataxin-3 are gone by day 13, compared to 
"HNHH" mutant-expressing flies which reach 50% death around day 21. When compared with 
the  control  flies  that  do  not  express  pathogenic  ataxin-3,  both  “Intact”  and “HNHH” live  a 
lifespan that  is  markedly shorter  (Figure 4.2B).  Control  flies  in  this  experiment  contain the 
cloning vector (pWalium10-moe; inserted at the attP2 site), without any ataxin-3 transgenes, and 
the sqh-Gal4 driver. Still, the “HNHH” mutation has a dramatic, early impact on the longevity of 
these flies when the transgene is expressed in all tissues of the fruit fly.  
Next, we assessed by western blotting the expression of ataxin-3 protein in one-day-old, 
whole-fly lysates where pathogenic ataxin-3 with an intact or mutated VCP-binding site was 
expressed using sqh-Gal4. Flies which harbor pathogenic ataxin-3 with intact VCP-binding show 
higher-molecular weight species, indicative of ataxin-3 SDS-resistant aggregates as early as one 
day  after  eclosion,  whereas  flies  with  a  mutated  VCP-binding  site  do  not  show  this  high 
molecular weight smear (Figure 4.2C).  
In Figure 4.2C and throughout the rest of this work, you will observe several ataxin-3-
positive  bands  in  western  blots.  The  band  highlighted  as  SDS-soluble  species  contains  the 
unmodified version of this protein (bottom-most band) and what could be a phosphorylated form 
of ataxin-3 (immediately above it in lighter exposures in some instances; this band is not always 
visible)  (Fei  et  al.,  2007;  Kristensen  et  al.,  2017;  Matos  et  al.,  2016).  The  asterisks  denote 
ubiquitinated  species  of  ataxin-3,  based  on  our  earlier  studies  with  this  protein  in  vitro,  in 
mammalian cells and in Drosophila (Todi et al., 2010; Todi et al., 2009; Tsou et al., 2013). We 
have drawn a dotted line to separate what we know are unmodified and ubiquitinated species of 
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ataxin-3 from the higher-molecular weight species. The smear above the dotted line is consistent 
with SDS-resistant ataxin-3 species, based on our earlier work with this protein (Blount et al., 
2014; Scaglione et al.,  2011; Todi et al.,  2009; Tsou et al.,  2013; Tsou et al.,  2015b). In our 
extensive  work  with  this  protein  in  vitro,  in  mammalian  cells,  in  Drosophila  and in  mouse 
models of this disease, we are confident that our delineation by the dotted line is a reasonable 
classification of ataxin-3 species that are SDS-soluble vs. not. The SDS- resistant species may 
contain higher-order aggregates of the SCA3 protein.  
As already noted, SCA3 is an age-related, progressive neurodegenerative disease. While 
aging the flies in the longevity experiment, we collected adults for western blot analysis after 
eclosion on day 1, 7 and 14 to examine the state of SDS-resistant and SDS-soluble species as 
flies age (Figure 4.2D).  We observe that on day 1, SDS-resistant species are already clearly 
present in flies that express the “Intact” pathogenic protein, whereas, with "HNHH" mutant flies, 
we see clear accumulation of SDS-resistant protein species on day 7. On day 1, "HNHH" flies 
have  noticeably  less  SDS-resistant  species  than  “Intact”  counterparts.  Both  “Intact”  and 
"HNHH" flies  show SDS-resistant  species  with age,  but  this  accumulation is  delayed in  the 
“HNHH” flies.  
To further examine the accumulation of insoluble aggregates of ataxin-3 with an intact or 
mutated VCP-binding site, we utilized differential centrifugation to separate whole fly lysates 
into a soluble, supernatant fraction and an insoluble, pellet fraction (Figure 4.2E) (Kim et al., 
2011; O'Rourke et al.,  2013; Santarriaga et al.,  2015; Yang et al.,  2014). We noticed a trend 
similar to what we saw with the SDS-resistant species in the previous panel, confirming our 
categorization of those species as aggregated ataxin-3. Flies expressing ataxin-3 with intact VCP-
binding  contain  insoluble  ataxin-3  aggregates  in  the  pellet  fraction  as  early  as  day  1,  and 
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accumulate over time. Flies expressing pathogenic ataxin-3 with impaired VCP-binding do not 
exhibit  marked insoluble aggregates in the pellet  until  day 7.  Accumulation of these species 
occurs with time, but is delayed compared to ataxin-3 with intact VCP-binding, similar to what 
we observe with SDS-resistant species in earlier blots.  
Altogether,  these  experiments  indicate  that  when the  VCP-binding site  of  pathogenic 
ataxin-3 is mutated, there is a delay in the accumulation of aggregated protein species in flies as 
compared  to  their  “Intact",  pathogenic  ataxin-3-expressing  counterparts.  Disrupting  the 
interaction  between  pathogenic  ataxin-3  and  VCP  leads  to  markedly  lower  toxicity  from 
pathogenic ataxin-3 during development and early on in the life of adult  flies.  These results 
prompted us to next explore the physiological impact of this mutation on the nervous system, the 
primary site of pathology in SCA3.  
4.2.4 Pathogenic ataxin-3 with mutated VCP-binding is less toxic in fly neurons  
Ataxin-3 is expressed in all tissues and cells in the human body. However, the polyQ 
disease SCA3 manifests as a neurodegenerative disorder with degeneration specifically in the 
brainstem and the cerebellum (Costa Mdo and Paulson, 2012). With fly genetics, we can direct 
the expression of ataxin-3 only in the nervous system using a neuronal-specific driver, elav-Gal4, 
and examine its effects in the fly.  
Western blot analysis from one-day-old whole-fly lysates where pathogenic ataxin-3 with 
an intact  VCP-binding site  is  expressed pan-neuronally shows the presence of  SDS-resistant 
ataxin-3 as early as day one in adults (Figure 4.3A). Comparing the impaired VCP-binding flies 
to those expressing the “Intact” protein, the high molecular weight smear is largely absent. The 
control flies used in this experiment were ones which contain the “Intact” pathogenic ataxin-3 
transgene without the pan-neuronal driver; thus, there was no ataxin-3 expression in these flies.  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Next, we aged adults to investigate how ataxin-3 expression in the nervous system affects 
their lifespan. Similarly to results we obtained when ataxin-3 forms are expressed in all tissues 
(Figure 4.2B), pan-neuronal expression of the VCP-binding site mutant delays lethality in adults 
compared to the “Intact” form (Figure 4.3B). A higher percentage of flies remain alive early on; 
we observed a 50% loss of flies expressing pathogenic ataxin-3 with intact VCP-binding by day 
25 whereas this reduction occurs around day 35 in flies expressing pathogenic ataxin-3 with 
impaired VCP-binding. However, even though in earlier time points more mutant “HNHH” flies 
remain alive, both fly lines have an average life span of 45 to 50 days (Figure 4.3B). Flies pan-
Figure 4.3. Mutating the VCP-binding site of pathogenic ataxin-3 delays its aggregation and toxicity when expressed pan-neuronally. 
In all panels, transgenes were expressed using the pan-neuronal elav-Gal4 driver. (A, C) Western blots from one-day-old flies (A) or flies of 
different ages (C) when pathogenic ataxin-3 with or without a mutation of its VCP-binding site is expressed in the nervous system. Control 
flies contained the Ataxin-3(SCA3)-Intact transgene, but without a Gal4 driver. Blots are representative of experiments repeated independently 
five times with the same outcomes.  NS: nonspecific band we observe sometimes with the monoclonal  anti-ataxin-3 antibody when this 
transgene is expressed pan-neuronally. (B) Longevity assay from adult Drosophilae pan-neuronally expressing pathogenic ataxin-3 with an 
intact or mutated VCP-binding site. Control flies contained the empty pWalium10-moe vector, without a transgene inserted at attP2, in the 
presence of the elav-Gal4 driver. Control flies lived up to ~90 days. 
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neuronally expressing either variant of pathogenic ataxin-3 
live  longer  than  those  expressing  the  same  constructs 
ubiquitously with the sqh-Gal4 driver. The difference in 
toxicity observed in this case is likely due to expression 
in all tissues of the fly as compared to only in the nervous 
system.  
We examined by western blotting whole fly lysates 
at three points: day 1, day 7, and day 14 (Figure 4.3C). 
Similar  to  the  results  with  ubiquitous  expression  of 
ataxin-3,  (Figure  4.2D),  SDS-resistant  pathogenic 
ataxin-3 species are evident at day one in flies expressing 
the  protein  with  intact  VCP-binding  (Figure  4.3C). 
Conversely, in those flies expressing pathogenic ataxin-3 
with  impaired  VCP-binding,  high  molecular  weight 
species are not prominent until day 7 (Figure 4.3C).  
SCA3  is  a  movement  disorder,  marked  by 
progressive  ataxia  followed  by  death  (Costa  Mdo  and 
Paulson, 2012). We tested neuronal function of flies when 
the  pathogenic  ataxin-3  proteins  were  expressed 
Figure 4.4. Flies that express pathogenic ataxin-3 with a mutated VCP-binding site are indistinguishable from non-ataxin-3 flies early 
on in motility assays. Results from a negative geotaxis assay used to assess the motility of flies expressing pathogenic ataxin-3 with or 
without the VCP-binding site mutation from “RKRR” to "HNHH". Ataxin-3 transgenes were expressed using the pan-neuronal elav-Gal4 
driver. Histograms show the mean ± SD, expressed as a percentage, of flies able to reach the top of the vial at the indicated time points. 
Asterisks: P<0.05, compared to “No Ataxin-3” control flies. P values are from two-tailed Student’s t-tests, comparing “Intact” and “HNHH” to 
“No Ataxin-3”. “No Ataxin-3” flies contained the elav-Gal4 driver and the empty pWalium10-moe vector inserted into the attP2 site. N=5 
independent repeats, totaling at least 50 flies per genotype.
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specifically in the nervous system by examining their motility against the gravitational index. We 
assessed how many flies reach the top of the vial within 5, 15 and 30 seconds. Adult flies were 
maintained over a period of four weeks and motility was assessed weekly (Figure 4.4). As early 
as  day  seven,  flies  expressing  the  “Intact”  pathogenic  protein  are  slower  than  control  flies 
containing the empty vector across all three time points. This difference increases markedly with 
age, and at four weeks of age the majority of flies do not reach the top of the vial even during the 
longest  time  interval,  30  seconds.  Conversely,  flies  expressing  pathogenic  ataxin-3  with  a 
mutated VCP-binding site perform as well as control counterparts for up to three weeks of age 
(Figure 4.4). We did not notice statistically significant reduction in the motili- ty of these flies 
early on, a testament to the reduced toxicity of this protein in neurons, compared to the “Intact” 
counterparts.  Finally,  at  four  weeks  of  age,  the  “HNHH”  flies  also  show  slower  motility 
compared  to  non-ataxin-3-expressing  controls,  but  still  perform  markedly  better  than  flies 
expressing pathogenic ataxin-3 with intact VCP-binding (Figure 4.4).  
In conclusion, when the VCP-binding site of ataxin-3 is mutated, accumulation of SDS-
resistant  species  in  neurons  is  delayed,  as  also  observed  with  ubiquitous  expression  of  the 
respective proteins. Flies pan-neuronally expressing pathogenic ataxin-3 with a mutated VCP-
binding  site  perform  significantly  better  than  their  “Intact”  pathogenic  ataxin-3-expressing 
counterparts in the negative geotaxis motility assay, comparable to control flies until three weeks 
of age. Reduced performance by the flies expressing pathogenic ataxin-3 with a mutated VCP-
binding site occurs after noticeable accumulation of SDS-resistant species by western blotting 
(Figure 4.3C), indicating a temporal relationship between aggregation and toxicity.  
4.2.5 Ataxin-3 with a mutated VCP-binding site is less toxic in Drosophila eyes  
Drosophila  eyes  serve  as  a  widely  accepted  model  to  study  degeneration  in  polyQ 
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diseases  and  other  proteotoxic  disorders  (Bonini  and  Fortini,  2003;  Kim  et  al.,  2018). 
Histological  sections of  the fly eye allow visualization of  degeneration and accumulation of 
proteinaceous  aggregates.  Using  the  GMR-Gal4  driver,  we  expressed  the  Ataxin-3(SCA3) 
transgenes in fly eyes and conducted histological assays at different time points to characterize 
the degeneration caused 
by  expression  of 
“Intact”  pathogenic 
ataxin-3 and the effects 
of  mutating  the  VCP-
binding  site  on  the 
phenotype.  
The  ommatidium  is 
the  functional  unit  of 
the  fly  eye.  Each  eye 
contains  approximately 
8 0 0  o m m a t i d i a 
arranged in a structured 
array.  The  highly 
iterative structure of the 
eye  makes  it  a  good 
Figure 4.5. Disrupting the interaction between ataxin-3 and VCP reduces toxicity in fly eyes. In all panels, transgenes were expressed using 
the eye-specific GMR-Gal4 driver. (A, B) Histological sections of fly eyes expressing pathogenic ataxin-3 with or without a mutation in the 
VCP-binding site  at  one week  (A) or four  weeks  (B)  of age.  Vector  Control  flies  contain the GMR-Gal4 driver,  as  well  as  the empty 
pWalium10-moe vector inserted at attP2. Red boxes: example of densely-staining structures. (C) Western blots from lysates of fly heads 
dissected from one-day-old flies. Fly eyes expressed pathogenic ataxin-3 with an intact or mutated VCP-binding site. Blots are representative 
of experiments repeated independently at least 5 times with the same outcomes. 
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model to easily and reliably observe perturbations arising from toxicity (Bonini  and Fortini, 
2003). Histological sections from one-week-old flies expressing pathogenic ataxin-3 with intact 
VCP-binding show that there is already some disruption of the internal ommatidial array of the 
eye compared to the control flies which did not express any ataxin-3 (Figure 4.5A, panel II 
compared to panel I).  Note the vacuolization of retinal structures when “Intact” pathogenic 
ataxin-3 is expressed in the fly eye. By comparison, eyes expressing the “HNHH” version of 
pathogenic ataxin-3 closely resemble control eyes, with a well-arranged ommatidial array and no 
visible signs of degeneration or aggregated structures (Figure 4.5A, panels III and IV).  As 
SCA3 is a progressive disease, we expected to observe more degeneration as flies aged over the 
course  of  four  weeks.  This  is  the  case  for  four-week-old  fly  eyes  expressing  the  “Intact” 
pathogenic  ataxin-3  protein,  where  we see  substantial  degeneration  and  loss  of  internal  eye 
structure  (Figure 4.5B,  panel  II).  We also  observe densely-staining structures,  indicative  of 
protein aggregates (red boxes; (Warrick et al., 2005; Warrick et al., 1998)). In "HNHH" eyes, we 
also begin to observe degeneration and some densely-staining structures (Figure 4.5B, panels 
III and IV). However, the ommatidial array is still clearly present and remains intact overall 
through the course of the examinations.  
We coupled histological assays with western blotting from dissected fly heads. Western 
blots  from  one-day-old  fly  heads  show  the  presence  of  ataxin-3  SDS-resistant  species,  as 
indicated by the high molecular weight smears, when we probe with ataxin- 3 antibody (Figure 
4.5C). We do not observe these species as prominently when the "HNHH" pathogenic ataxin-3 is 
expressed in the fly eyes (Figure 4.5C).  We conclude that mutating the VCP-binding site of 
pathogenic ataxin-3 delays the formation of SDS-resistant species and slows the degeneration of 
fly eyes, similar to what we observe when these ataxin-3 forms are expressed in other tissues.  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Altogether, the studies conducted in the various fly tissues with the different forms of 
pathogenic ataxin-3 lead us to conclude that its binding to VCP influences the aggregation and 
ensuing  toxicity  of  pathogenic  ataxin-3.  To  further  probe  into  this  model,  we  turned  to 
endogenous VCP.  
4.2.6 Knockdown of VCP improves degeneration caused by pathogenic ataxin-3  
The results that we obtained with our experiments above indicate that pathogenic ataxin-3 
protein  is  less  toxic  when  its  VCP-binding  site  is  mutated.  We  wanted  to  confirm  these 
differences in phenotype by targeting VCP itself.  VCP is an essential protein with numerous 
important functions in the cell. Knockdown of VCP in the whole fly, as well as in the nervous 
Figure  4.6.  Knockdown of  VCP in  fly  eyes  improves  degeneration  caused  by  pathogenic  ataxin-3.  In  all  panels,  transgenes  were 
expressed using the eye-specific GMR-Gal4 driver. (A) Histological sections of four-week-old fly eyes expressing pathogenic ataxin-3 with or 
without VCP RNAi. Vector Controls contained the GMR-Gal4 driver and empty pWalium10-moe vector on the same genetic background as 
the RNAi lines. (B) Western blots of one-day-old fly head lysates when pathogenic ataxin-3 is expressed alone or with VCP RNAi in fly eyes. 
Red dotted line: portion of SDS-resistant ataxin-3 species most clearly diminished in intensity by the knockdown of VCP. Black dotted line 
was drawn consistent with the same line in blots from prior figures. Blots are representative of experiments repeated independently three times 
with the same outcomes. (C) Quantification of VCP protein levels from panel B and other, independent repeats, in the presence or absence of 
RNAi targeting VCP from four independent experiments. Means ± SD. Asterisks: P<0.05. P values are from two-tailed Student’s t-tests, 
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system, is developmentally lethal, but knockdown of VCP in fly eyes is well tolerated (our own, 
unpublished  observations).  Thus,  we  examined  whether  knockdown  of  VCP  in  fly  eyes 
expressing pathogenic ataxin-3 with an intact VCP-binding site impacts the structure of the eye. 
From  histological  sections  at  four  weeks  of  age,  as  shown  above  (Figure  4.5B), 
expression of “Intact” pathogenic ataxin-3 in the eyes using GMR-Gal4 is toxic and causes the 
breakdown of the ommatidial array (Figure 4.6A). We used two different RNAi lines targeting 
fly VCP. As shown in Figure 4.6C, knockdown of VCP by each RNAi line leads to statistically 
significant reduction in VCP protein levels in the fly head. An important note here is that the 
blots  underestimate  the  extent  of  VCP reduction.  This  is  because  we  target  RNAi  to  the 
Drosophila eyes, but, unable to isolate only the eyes, we examined protein levels from intact, 
dissected fly heads, as is customary in fly studies.  
Knockdown of VCP in fly eyes leads to improvement of pathology caused by ataxin-3. 
As shown in Figure 4.6A, knocking down VCP with either RNAi-1 or -2 reduces ommatidial 
disarray in the presence of pathogenic ataxin-3. VCP RNAi-1 is not as effective as RNAi-2 at 
suppressing the degenerative phenotype. This could be due to the extent of VCP knockdown. 
RNAi-1 targeting VCP consistently provides reduction of VCP protein based on western blots, 
whereas the extent of knockdown with RNAi-2 is not as consistent, as indicated by the standard 
deviation bars in Figure 4.6C. There may be a fine line between beneficial knockdown of VCP 
to  suppress  ataxin-3-dependent  pathology  and  too  much  suppression,  which  might  be 
problematic, on and of itself, to the eye since we are targeting a crucial gene. RNAi-1 might be 
achieving this  level  of  some improved pathology but also inherent  toxicity due to low VCP 
levels. Nevertheless, both RNAi lines present with improved pathology compared to pathogenic 
ataxin-3  with  intact  VCP-binding  in  the  absence  of  RNAi,  supporting  our  model  that  the 
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interaction between VCP and ataxin-3 is important for the toxicity of the SCA3 protein in vivo. 
Concomitant  with  improved  pathology,  we  observe  reduced  levels  of  SDS-resistant 
species of ataxin-3 when VCP is knocked down (Figure 4.6B). In Figure 4.6B, and to a lesser 
extent in earlier figures, a higher proportion of SDS-soluble ataxin-3 seems to be ubiquitinated in 
flies when VCP is knocked down or the VCP-binding site is mutated. It is possible that when 
ataxin-3 proteins bind to VCP they are brought in close proximity and deubiquitinate each other. 
In conclusion, we observe decreased toxicity from ataxin-3 when VCP is knocked down 
in fly eyes, indicating that VCP enhances ataxin-3 aggregation and toxicity.  
4.2.7 Correlating ataxin-3 SDS-resistant species to fly longevity  
Our results with the ubiquitous and pan-neuronal drivers show the presence of SDS-re- 
sistant ataxin-3 species with the “Intact” version before we observe marked lethality in flies. We 
sought to further examine the temporal relationship between the SDS-resistant species and death. 
In our previous experiments,  expression of pathogenic ataxin-3 proteins (intact and impaired 
VCP-binding)  was  driven  throughout  development  and  adulthood.  In  the  next  round  of 
experiments, we used fly genetics to initiate ataxin-3 expression after eclosion and for specific 
points  of  time  during  adulthood  to  examine  the  correlation  between  fly  death  and  and  the 
accumulation of SDS-resistant ataxin-3 species.  
We  used  the  tissue  specific,  inducible  GeneSwitch  Gal4  (Nicholson  et  al.,  2008; 
Osterwalder et al., 2001; Roman and Davis, 2002; Sujkowski et al., 2015). Using this system, the 
pan-neuronal driver, elav-Gal4(GS) does not yield expression of ataxin-3 constructs until flies 
are fed RU-486, the compound which activates the driver.  In our setup,  we reared flies that 
harbor the driver and ataxin-3 constructs in fly media without RU-486, and then switched them 
to RU-486-containing food on day 1 as adults. Offspring were then aged on RU-486-containing 
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media and collected for western blotting on day 1, 4, 7, 10, 14, 21, 28 and 35. During this time, 
we also examined their longevity.  
When pathogenic ataxin-3 with intact VCP-binding is driven by the RU-486-inducible 
elav-Gal4(GS) driver, we begin to more clearly observe SDS-resistant species around days 4-7; 
the intensity of these smears increases over time (Figure 4.7A). When expression of pathogenic 
ataxin-3 with the “HNHH” mutation is induced, we observe SDS-resistant species more clearly 
around days 10-14. These smears also increase in intensity over time (Figure 4.7A). When the 
samples are compared side-by-side, on the same PVDF membrane, the difference in the timing 
of appearance of SDS-resistant species among the two forms of ataxin-3 becomes noticeable 
(Figure 4.7B). We observe comparable levels of SDS-resistant species between the two forms of 
Figure 4.7. Correlation of ataxin-3 SDS-resistant species and longevity in flies. In all panels, transgenes were expressed using the pan-
neuronal,  RU-486-inducible  elav-Gal4(GS)  driver.  (A,  B)  Western  blots  of  fly  lysates  at  the  indicated  ages  (days)  when  pan-neuronal 
expression of pathogenic ataxin-3 with intact or impaired VCP-binding was induced immediately upon eclosion from the pupal case. Blots in 
each panel are from independent biological repeats. NS: non-specific band. Results are representative of experiments repeated independently 
four or more times with the same outcomes. (C) Longevity of flies when pan-neuronal expression of pathogenic ataxin-3 with or without a 
mutation on the VCP-binding site is induced upon eclosion from the pupal case. 
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pathogenic ataxin-3 around days 7 and 14 (“Intact” vs. "HNHH", respectively) and later, around 
days 14 and 21 (“Intact” vs. "HNHH", respectively). Based on longevity curves, (Figure 4.7C), 
temporally-induced  expression  of  pathogenic  ataxin-3  with  impaired  VCP-binding  leads  to 
lethality at later time points than the version with intact VCP-binding, correlating with delayed 
appearance  of  SDS-resistant  species  with  the  “HNHH” version  of  the  SCA3 protein.  These 
results  support  our  findings  from  various  tissues  that  the  “HNHH”  mutation  delays  the 
appearance of higher-molecular weight, SDS-resistant, ataxin-3-positive species in western blots, 
as well as the toxicity of this protein, compared to the “Intact” version.  
4.2.8 SDS-resistant species of pathogenic ataxin-3 are stable once formed  
Lastly, we utilized the power of the RU-486-dependent elav-Gal4(GS) driver to examine 
how  stable  the  SDS-resistant  species  of  pathogenic  ataxin-3  are  in  vivo.  We  wondered  if 
eliminating the production of additional ataxin-3 could lead to time-dependent dissipation of the 
protein itself, and if mutating its VCP-binding site influences this process. We have shown before 
that ataxin-3 is a stable protein in the cellular environment (Todi et al., 2007). Thus, we chased 
ataxin-3 for 14 days after we stopped its production by removing RU-486 from the fly media. To 
begin with comparable levels of the SDS-resistant species, we induced pathogenic ataxin-3 with 
an intact VCP-binding site for 14 days and the “HNHH” mutant form for 21 days in adult flies, 
based on results  from Figure 4.7B.  Flies were reared in media without RU-486.  They were 
switched to media with the inducer on day 1 as adults (Figure 4.8A). 
As shown in Figure 4.8B, the SDS-resistant species are stable for the 14 days that we 
conducted our chases for both pathogenic ataxin-3 species. Whereas the SDS-soluble species 
diminish in intensity over time, the intensity of the SDS-resistant species does not decrease. 
Lastly, we tested if the physiological phenotypes of “Intact” and "HNHH" flies differ when the 
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aggregated species are present at comparable levels, following the same induction and temporal 
parameters  described above.  In motility assays,  we find no statistically significant  difference 
between the performance of flies expressing either version of pathogenic ataxin-3 (Figure 4.8C). 
Figure 4.8. Ataxin-3 aggregates are stable, independently of VCP-binding capacity. In panels A-C, transgenes were expressed using the 
pan-neuronal, RU-486-inducible elav-Gal4(GS) driver. (A) Outline of the experimental design for pulse-chases of pathogenic ataxin-3 with an 
intact or mutated VCP-binding site. (B) Western blots from whole fly lysates where pan-neuronal expression of pathogenic ataxin-3 with or 
without the VCP-binding mutation was induced and chased for the indicated time points. Blots are representative of experiments repeated 
independently three times with the same outcomes. (C) Results from negative geotaxis assays assessing the motility of flies when pathogenic 
ataxin-3 was induced and then chased. Ataxin-3(SCA3)-Intact was induced for 14 days, and Ataxin-3(SCA3)-HNHH was induced for 21 days. 
Motility was assessed on Day 1, 21, and 28 of the flies’ total adult lifespan. Histograms represent means ± SD, expressed as a percentage. P 
values are from two-tailed Student’s t-tests, comparing Ataxin-3(SCA3)-HNHH to Ataxin-3(SCA3)-Intact. No significant difference in motor 
performance was found between Ataxin-3(SCA3)-Intact and Ataxin-3(SCA3)-HNHH. (D) Model: Ataxin-3 directly binds to VCP through the 
VCP-binding site on its C-Terminal half. VCP acts as a nucleating agent and increases the local concentration of ataxin-3, leading to higher 
chances of interaction and aggregation of the SCA3 protein. 
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This  suggests  that  the  difference in  motility  phenotypes  for  the  “Intact”  and “HNHH” flies, 
which we observed in Figure 4.4, is dependent on the different amounts of aggregated species, 
rather  than  the  intrinsic  nature  of  the  “Intact”  vs  "HNHH"  proteins  themselves.  We  also 
conducted a similar experiment, with similar results, where we induced expression of pathogenic 
ataxin-3 with an intact VCP-binding site for 7 days and mutated VCP-binding site for 10 days, to 
address the possibility that aggregated species formed earlier and present at lower levels might 
be more easily dispelled. This was not the case (Figure 4.9).  
Altogether, the in vivo chase studies indicate highly stable aggregated species of ataxin-3 
Figure 4.9. Ataxin-3 aggregates formed earlier in the fly lifespan are also highly stable (Supplemental to Figure 4.8). (A) Outline of the 
experimental design for pulse-chases of pathogenic ataxin-3 with an intact or mutated VCP-binding site. (B) Western blots from whole fly 
lysates where pan-neuronal expression of pathogenic ataxin-3 with or without the VCP-binding mutation was induced and chased for the 
indicated time points. Blots are representative of experiments repeated independently three times with the same outcomes. (C) Results from 
negative geotaxis assays assessing the motility of flies when pathogenic ataxin-3 was induced and then chased. Ataxin-3(SCA3)-Intact was 
induced for 7 days, and Ataxin-3(SCA3)-HNHH was induced for 10 days. Motility was assessed on Day 1, 21, and 28 of the flies’ total adult 
lifespan. Histograms represent means ± SD, expressed as a percentage. Asterisk: P<0.05, compared to Ataxin-3(SCA3)-Intact flies. 
P values are from two-tailed Student’s t-tests, comparing Ataxin-3(SCA3)-HNHH to Ataxin-3(SCA3)-Intact. 
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and lack of a role for the VCP-binding site of ataxin-3 in their dissipation over time.  
4.3 Discussion  
We investigated the interaction of the SCA3 protein,  ataxin-3,  with its  direct  binding 
protein,  VCP,  and  the  effect  of  this  interaction  in  SCA3-like  degeneration  in  Drosophila. 
Ataxin-3  was  reported  previously  to  function  with  VCP to  regulate  degradation  of  ERAD 
substrates (Wang et al., 2006; Zhong and Pittman, 2006). Interestingly, while ataxin-3 has been 
ascribed various roles in cell culture-based studies, different knockout mouse lines that targeted 
the atxn3 gene failed to show that this protein is a necessary entity in an intact mammal (Schmitt 
et al., 2007; Switonski et al., 2011). Based on the knockout lines, we hypothesized some time 
ago that targeting the ataxin-3 protein to enhance its degradation might have therapeutic benefits. 
In those studies, we found that the VCP-ataxin-3 interaction did not impact the levels or turnover 
rate of ataxin-3 degradation in cultured mammalian cells or in vivo in Drosophila (Blount et al., 
2014). We also found that the VCP-binding capability of ataxin-3 was dispensable for its role in 
the fly, where the SCA3 protein serves a neuroprotective role (Tsou et al., 2015b). The VCP-
ataxin-3 interaction was described in detail by the Wanker and Bonini groups over a decade ago. 
In that work, Boeddrich et. al. reported that ataxin-3 and VCP bind each other directly through a 
VCP-binding site  on the C-terminus of  ataxin-3 (Boeddrich et  al.,  2006).  A model  emerged 
where binding of multiple ataxin-3 proteins by a single VCP hexamer brings SCA3 proteins in 
close physical contact, thus expediting, or nucleating, early steps of their fibrillization. Intrigued 
by that work and by our own findings that the VCP-ataxin-3 interaction does not impact the 
degradation  of  ataxin-3  or  its  function  in  the  fly,  we investigated  how this  binding impacts 
ataxin-3 aggregation and toxicity in vivo over time and in different tissues.  
We found that accumulation of SDS-resistant species and insoluble aggregates occurs 
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faster  in  flies  expressing  pathogenic  ataxin-3  with  an  intact  VCP-binding  site  than  in  flies 
expressing pathogenic ataxin-3 with a mutated VCP-binding site. The SDS-resistant species that 
we observe in  western blots  likely  consist  of  lower-  and higher-order  multimeric  species  of 
pathogenic ataxin-3. The insoluble pellet fractions we obtained from differential centrifugation 
could contain higher-order ataxin-3 multimers and oligomers (O'Rourke et al., 2013). Coincident 
with a delay in pathogenic ataxin-3 aggregation when its VCP-binding site is mutated (or when 
VCP is knocked down in fly eyes), we noticed reduced toxicity from this version of the SCA3 
protein, compared to the “Intact” form. In each of the studies we conducted, the form of ataxin-3 
with impaired VCP-binding led to reduced toxicity, especially early on in the life of the flies. In 
fact, at early stages, fly motility was entirely non-impacted by pathogenic ataxin-3 with impaired 
VCP-binding. Later on, these flies did perform poorly when compared to flies not expressing the 
SCA3  protein,  but  still  much  better  than  the  “Intact”  flies.  Thus,  while  interrupting  the 
interaction between ataxin-3 and VCP had an ameliorative effect early on, in later stages the 
disease protein still proved toxic. This is an important finding, as it suggests that VCP enhances, 
but does not play a vital role, in the overall toxicity of the SCA3 protein. Also, from a therapeutic 
point of view, interrupting the interaction of ataxin-3 with VCP might have beneficial effects, but 
perhaps would not reach “curative” properties. The latter statement is further supported by the 
data that inducing the expression of ataxin-3 only in adults still leads to premature death in flies, 
and that mutating the VBM delayed lethality, but did not fully suppress it.  
Collectively,  our  studies  support  a  role  for  VCP  in  the  early  stages  of  ataxin-3 
aggregation, consistent with a nucleation role for the hexamer put forth based on in vitro work 
(Boeddrich  et  al.,  2006)  (Figure  4.8D).  Non-pathogenic  ataxin-3  itself  has  a  propensity  to 
aggregate. This is believed to happen through a two-step process based on in vitro data with 
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reconstituted systems using purified, recombinant proteins (Ellisdon et al., 2006; Masino et al., 
2011; Masino et al., 2004). Ataxin-3 that does not contain an expanded polyQ tract is thought to 
first dimerize through the catalytic Josephin Domain in the structured N-terminus. In a second, 
less understood step, the C-terminal tails of the proteins come together to create a ‘bead-on-a-
string’-type structure, and these further assemble into SDS-soluble protein aggregates (Ellisdon 
et al., 2006; Masino et al., 2011). This process is also thought to occur in the same two-step 
manner when ataxin-3 contains an expanded polyQ, although in that instance highly stable, SDS-
resistant aggregates form in vitro (Ellisdon et al., 2006; Masino et al., 2011). We propose that 
VCP acts as a nucleating agent in initial ataxin-3 fibrillization. Ataxin-3 directly binds to VCP 
through its VCP-binding site. A VCP hexamer could bind up to six ataxin-3 proteins (Boeddrich 
et al., 2006; Xia et al., 2016). VCP, by binding to ataxin-3, increases the local concentration of 
the protein and also increases the likelihood of binding between ataxin-3 molecules and eventual 
formation into larger protein aggregates (Figure 4.8D). Inhibiting this interaction, or reducing 
levels of VCP available for this step decreases aggregation and ensuing toxicity.  
There was a recent study by the Loll lab that contradicts the model presented above. 
Utilizing wild type (non-pathogenic) ataxin-3 and VCP proteins produced in bacteria, their in 
vitro biochemical and electron microscopy work indicated that each VCP hexamer is bound by a 
single,  wild  type  ataxin-3  (Rao  et  al.,  2017).  Work  by  Wanker  and  Bonini  hinted  at  a 
stoichiometry of 4:1 ataxin-3:VCP (Boeddrich et al.,  2006). Our own data in Drosophila are 
consistent  with  a  stoichiometry  different  than  1:1.  It  could  be  that  the  VCP:ataxin-3 
stoichiometry is 1:1 for wild type ataxin-3, but different for pathogenic ataxin-3. Also, unlike in 
an isolated system, it is possible that additional factors impact the stoichiometry between these 
two proteins in vivo. This is an area that requires additional investigation in vivo.  
 72
In summary, the VCP-binding site of ataxin-3 has a significant role on the aggregation 
and toxicity of the SCA3 protein, underscoring the importance of non-polyQ domains in this 
disease and pointing to the ataxin-3-VCP interaction as a potential therapeutic target. The model 
for VCP-mediated fibrillization may extend beyond SCA3, since VCP also interacts with other 
polyQ proteins (Fujita et al., 2013).  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CHAPTER 5: CONCLUSIONS
SCA3 is  a  devastating  neurodegenerative  disease  for  which  the  causative  biology  is 
currently  unknown.  As  such,  ataxin-3’s  non-polyQ domains  and  physiological  functions  can 
provide us with valuable context for what mechanisms go awry in SCA3 and how to ameliorate 
them. The Josephin domain, sumoylation at K166, and phosphorylation at several residues are 
known to modulate toxicity of ataxin-3, but otherwise not much is known about how protein 
context plays into SCA3. For this reason, we explored how ataxin-3’s interactions with Rad23 
and VCP at specific binding sites can influence its disease properties.  
We  found  that  Rad23-binding  at  UbS2  regulates  ataxin-3’s  stability,  autoprotective 
function, and overall toxicity in vivo. Since reducing levels of polyQ proteins can be beneficial in 
these diseases (Esteves et al., 2017; Keiser et al., 2016; Wang, 2017), lowering ataxin-3 stability 
by  targeting  the  Rad23-UbS2  interaction  seemed  like  a  reasonable  therapeutic  approach. 
However,  our  results  demonstrate  the  complexity  of  the  Rad23-UbS2  interaction,  since  it 
controls  several  of  ataxin-3’s  properties.  Until  more  is  known  about  how  Rad23  regulates 
ataxin-3’s neuroprotective function, this interaction is likely not a viable therapeutic target for 
SCA3. As such, future work should focus on elucidating the mechanism for ataxin-3 and Rad23’s 
upregulation of DnaJ-1. Experiments testing whether ataxin-3 and Rad23 bind directly to the 
DnaJ-1 promoter, or influence the activity/stability of transcriptional regulators (HATs, HDACs, 
transcription  factors,  etc.)  would  be  an  excellent  place  to  start.  Moreover,  the  discrepancies 
between cell/fly and mouse studies emphasize the need to confirm these potential  protective 
mechanisms in mammalian systems. If ataxin-3 is not neuroprotective in humans, then disrupting 
the Rad23-UbS2 interaction could be reconsidered as a potential therapeutic avenue.  
Our work with VCP indicates that this protein can also influence ataxin-3 toxicity, but by 
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a  different  mechanism.  Our  data  suggests  that  VCP acts  as  a  seeding  factor  for  ataxin-3 
aggregation, likely by bringing multiple ataxin-3 proteins in closer contact and increasing their 
chances of aggregation. Mutating the VCP-binding site reduces ataxin-3 aggregation, which is 
intriguing from a therapeutic perspective,  since increasing solubility of polyQ proteins could 
improve disease outcomes (Esteves et al., 2017; Wang, 2017). Decoy peptides that mimic the N-
terminus  of  VCP may be  a  way to  reduce both  ataxin-3’s  binding to  endogenous  VCP and 
subsequent aggregation in vivo. To accomplish this, future experiments will aim to identify the 
region of VCP’s N-terminus that most efficiently binds ataxin-3, while remaining stable in an in 
vivo environment and without causing adverse toxicity. It will also be important to identify the 
physical  nature  of  the  binding  interaction  between  ataxin-3  and  VCP,  since  the  nucleation 
hypothesis has not been formally confirmed.  
The physiological purpose of ataxin-3’s interaction with VCP is not fully understood. 
Past studies have linked ataxin-3 and VCP as potential partners in ERAD and the UPS, but the 
molecular mechanisms remain to be clarified (Doss-Pepe et al., 2003; Wang et al., 2006; Zhong 
and Pittman, 2006). Recently, VCP has been linked to defects in DNA repair in multiple polyQ 
disorders (Fujita et al., 2013). Considering VCP and ataxin-3 are already known to co-localize at 
sites of DNA damage (Ackermann et al., 2016), it would be very interesting to investigate if VCP 
and ataxin-3 co-regulate DNA repair pathways. Moreover, Rad23 is also an established entity in 
DNA repair (Dantuma et al., 2009). It is possible that these proteins might function as a complex 
at  the  DNA,  similar  to  their  proposed  role  in  the  UPS  (Doss-Pepe  et  al.,  2003).  Overall, 
additional studies to elucidate the interplay between VCP, ataxin-3, and Rad23 will enhance our 
appreciation for the physiological significance of these interactions in normal and disease states.  
Ataxin-3 knockout studies report that the mice do not exhibit a decrease in viability or 
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fecundity (Schmitt et al., 2007; Switonski et al., 2011). However, a complete characterization of 
these models under stress and non-stress conditions remains to be conducted. Such studies could 
reveal  an  essential  role  for  ataxin-3  that  was  previously  undetected.  It  is  also  possible  that 
another  DUB  is  compensating  for  the  loss  of  ataxin-3  in  these  models.  The  generation  of 
catalytically  inactive  ataxin-3  knock-in  mice  could  enhance  our  understanding  of  ataxin-3’s 
significance in protein quality control, DNA repair, and other pathways.  
Finally, there are some notable similarities between our results and findings related to 
other polyQ disorders, which were discussed in Chapter 1. Interestingly, the influence of UbS2-
Rad23  on  ataxin-3’s  stability  is  remarkably  similar  to  the  relationship  between  14-3-3  and 
ataxin-1 turnover (Chen et al., 2003). Moreover, the ability of the VCP-binding site to enhance 
ataxin-3  aggregation  is  in  agreement  with  multiple  studies  that  demonstrate  the  ability  of 
domains flanking the polyQ tract to modify its solubility (Adegbuyiro et al., 2017; Nozaki et al., 
2001;  Robertson  and  Bottomley,  2010).  Thus,  our  findings  related  to  SCA3  could  have 
implications  for  other  polyQ  diseases,  and  vice-versa.  Undoubtedly,  efforts  to  unravel  the 
complexities of protein context will be invaluable to understanding the biology of these diseases 
and how to treat them. Moving forward, an appreciation for both the similarities and differences 
between the polyQ disorders will facilitate new collaborative discoveries in the field.
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The  polyglutamine  (polyQ)  disease  family  is  composed  of  nine  neurodegenerative 
diseases caused by CAG trinucleotide repeat expansions in the associated genes. Although these 
diseases  are  caused  by  similar  mutations,  the  polyQ proteins  are  otherwise  structurally  and 
functionally unique. Thus, the protein domains surrounding the polyQ tracts, as well as their 
interacting partners,  are thought  to be critical  to  the pathogenesis  of  these clinically distinct 
diseases.  Spinocerebellar  ataxia  type  3  is  caused  by  polyQ  expansion  of  ataxin-3,  a 
deubiquitinating enzyme implicated in  protein  quality  control,  transcriptional  regulation,  and 
DNA repair. Rad23 and VCP are two of ataxin-3’s protein quality control partners that bind at its 
Ubiquitin-binding site 2 and VCP-binding site, respectively. To learn more about protein context 
in SCA3, we generated new transgenic Drosophila lines that express pathogenic ataxin-3 with 
these protein-binding sites intact or mutated. Through a battery of physiological and biochemical 
assays, we observed that ataxin-3’s interaction with Rad23 regulates the stability, autoprotection, 
and toxicity of the SCA3 protein. We also find that VCP can modulate the aggregation propensity 
and subsequent toxicity of ataxin-3. Altogether, our findings provide insight into SCA3 biology 
and potential avenues for therapeutic intervention.  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